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1. THE ENDOCANNABINOID SYSTEM  
The history of the endocannabinoid system (ECS) started very far away in the time: in fact, the Indian 
and Chinese populations, for the treatment of pain and anxiety, reported the use of Cannabis Sativa 
plants more than three thousand years ago1.  
In addition to cannabis fibres, also seeds, leaves, flowers and extracts have been used in medicine and 
in social or religious rituals of different cultures for thousands of years.  
Over the centuries, cannabis has also been used as anaesthetic and anthelmintic, in the treatment of 
diarrhoea, migraine, spasmodic asthma and to treat opiates’ and alcohol’s withdrawal symptoms. 
More recently in history (1964), the structure of the main active component Δ9-THC 
(tetrahydrocannabinol) was described2, opening the field for the comprehension of action’s 
mechanism of this molecule and its related analogues, which are a pool of more than 80 compounds. 
Among these molecules, that are the so - called “Cannabinoids” (fig. 1), the most important in terms 
of activity are tetrahydrocannabinol (Δ9-THC), cannabinol (CBN) and cannabidiol (CBD). 
 
Fig. 1: Cannabis Sativa’s main components 
The description of Δ9-THC structure and the understanding that its activity was stereochemistry-
dependent3 led to the hypothesis of a receptor-driven mechanism of action4. 
In early 90’s, an orphan G-protein coupled receptor (GPCR) that bound cannabinoids (with the 
expected affinity and stereo selectivity) was discovered and named CB1 cannabinoid receptor
5, 
followed very soon by another receptor with peripheral localisation - the CB2 cannabinoid receptor
6. 
Since then, researchers have made major progress due to the discovery of their endogenous ligands 
and the enzymes responsible for the synthesis and inactivation of these molecules. 
This complex signalling system is known as endocannabinoid system (ECS). 
The core of endocannabinoid system functioning are derivatives of unsaturated fatty acids with 
ethanolamine, glycerol, or glycerol ether head groups and are known as “Endocannabinoids” (ECs). 
                                                          
1 Russo, E. B. et al.; Chem. Biodivers. 4, 2007, 1614-1648. History of cannabis and its preparations in saga, science, and sobriquet. 
2 Gaoni, Y. et al.; J. Am. Chem. Soc., 86, 1964, 1646-1647. Isolation, structure and partial synthesis of an active constituent of hashish 
3 Mechoulam, R. et al.; Prog. Med. Chem., 24, 1987, 159-207. Towards cannabinoid drugs. 
4 Little, P. J. et al.; J. Pharmacol. Exp. Ther., 247, 1988, 1046-1051. Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. 
5 Matsuda, L. A. et al.; Nature, 346, 1990, 561-564. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. 
6 Munro, S. et al.; Nature, 365, 1993, 61-65. Molecular characterization of a peripheral receptor for cannabinoids. 
3 
 
The structures of the most important endocannabinoids are shown in fig. 2: the first to be isolated was 
anandamide (N-arachidonoyl ethanolamine, AEA)7, followed by other ethanol amine derivatives. 
such N-homo-γ-linolenoyl ethanolamine and N-docosatetraenoyl ethanolamine8. 
 
Fig. 2: Endocannabinoids structures 
                                                          
7 Devane, W. A. et a.;  Science, 258 (5090), 1992, 1946-1949. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. 
8 Hanus, L. et al.; J. Med. Chem., 36 (20), 1993, 3032-3034. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid 
receptor. 
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Afterwards, the second most important endogenous compound sn-2-arachidonylglycerol (2-AG)9 was 
described, and showed to be present in the brain in much higher concentration than AEA (170-fold)10. 
An additional glycerol-related compound, 2-eicosa-5’,8’,11’,14’-tetraenylglycerol (2-AG ether, 
noladin ether) was identified11, followed by other endogenous cannabinoids such N-arachidonoyl 
dopamine (NADA)12 and virodhamine13. 
The identification of endogenous ligands for CB receptors brought to light the enzymes that are 
responsible for the inactivation of these molecules.  
The Fatty Acid Amide Hydrolase (FAAH)14 acting prevalently on AEA; the Monoacylglycerol 
Lipase (MAGL)15, dedicated to the block of monoacylglycerols; the N-Acylethanolamine-
hydrolysing Acid Amidase (NAAA)16 responsible for the hydrolysis of different N-acyl 
ethanolamines (NAEs), such N-palmitoyl ethanolamine (PEA), N-oleoyl ethanolamine (OEA) and N-
stearoyl ethanolamine (SEA). 
 
The complexity of the system, the large number of molecules implied in its functioning and the deep 
involvement of Ecs in many physiological and pathological conditions17, justify the great interest 
around this field, about which – at the moment – we are far from a complete understanding. 
                                                          
9 Mechoulam, R. et al.; Biochem. Pharmacol., 50, 1995, 83-90. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to 
cannabinoid receptors. 
10 Stella, N. et al.; Nature, 388 (6644), 1997, 773-778. A second endogenous cannabinoid that modulates long-term potentiation. 
11 Hanus, L. et al.; Proc. Natl. Acad. Sci. USA, 98 (7), 2001, 3662-3665. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 
receptor. 
12 Bezuglov, V. et al.; Bioorg Med Chem Lett, 11 (4), 2001, 447-449. Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids 
with dopamine.  
13 Porter, A. C. et al.; J Pharmacol Exp Ther, 301 (3), 2002, 1020-1024. Characterization of a novel endocannabinoid, virodhamine, with antagonist 
activity at the CB1 receptor. 
14 Cravatt, F. et al.; Proc. Natl. Acad. Sci. USA, 94, 1997, 2238-2242. Molecular characterization of human and mouse fatty acid amide hydrolases. 
15 Boyer, J. et al.; J. Clin. Endocrinol. Metab. 53, 1981, 143-148. Human Erythrocyte Monoester Lipase: Characterization and Radiochemical Assay of 
the Cell-Bound Enzyme in Normal Subjects. 
16 Tsuboi, K. et al.; CHEMISTRY & BIODIVERSITY, 4, 2007, 1914-925. The N-Acylethanolamine Hydrolyzing Acid Amidase (NAAA). 
17 Di Marzo, V. et al.; Curr Opin Lipidol, 18, 2007, 129-140. Endocannabinoids and the regulation of their levels in health and disease. 
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1.1 Biosynthesis and release of endocannabinoids  
The biosynthesis of endocannabinoids is a complex process which occur at the level of post-synaptic 
cells only after the arrival of an adequate signal; in fact, the Ecs are known to be post-synaptic 
retrograde mediators – thing that justify, for example, their implication in synaptic plasticity 
modulating the signals mediated by other transmitters18. 
The depolarisation of the post-synaptic cell is mediated by the release, from the pre-synaptic one, of 
different neurotransmitters in the synaptic space. 
The interaction between the transmitter and its post-synaptic receptor can trigger different effects 
(inhibition, excitation, second messenger cascade’s activation) and – basing on the type of cell – it 
can produce the on-site synthesis and release of 2-AG, AEA or other Ecs19, through the elevation of 
intracellular calcium. 
 
 1.1.1 Endocannabinoid signalling via Anandamide  
Anandamide (AEA) was the first endogenous cannabinoid isolated and characterized, acting as 
agonist on the same receptors of THC. 
AEA is predominantly generated in vivo from phospholipid precursors (scheme. 1): and subsequently 
degraded intracellularly by fatty acid amide hydrolase (FAAH). 
The depolarisation-induced influx of calcium into the post-synaptic neuron causes the activation of 
an enzyme called N-acyl trasferase (NAT); this enzyme catalyses the first conversion necessary for 
Ecs biosynthesis, transforming membrane’s phosphatidyl ethanolamine (PE) into N-acyl-phophatidyl 
ethanolamine (NAPE)20.  
A first direct way leading to the formation of NAEs is NAPE hydrolysis by a Ca2+-sensitive NAPE-
phospholipase D (NAPE-PLD), which seems to be kept in a constitutively active form21. 
The evidence that low calcium levels are not correlated to a complete block of NAEs biosynthesis22, 
suggests the existence of other different synthetic pathways. 
One pathway passes through the formation of Lyso-NAPE and glycerophospho-NAE (GP-NAE) 
thanks to a double O-deacylation of NAPE23; the action of a Lyso-PLD on Lyso-NAPE and of an 
enzyme called glycerophosphodiesterase 1 (GDE1) on GP-NAE leads to the formation of NAEs. 
                                                          
18 Kano, M. et al.; Physiol. Rev., 89, 2009, 309-380. Endocannabinoid-mediated control of synaptic transmission. 
19 Pertwee, R. G. et al.;  Br. J. Pharmacol., 153 (2), 2010, 199-215. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-
tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. 
20 Di Marzo, V.et al.; Nature 372, 1994, 686-691. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. 
21 Wang, J. et al.; Neuropharmacology, 54, 2008, 8-15. The stimulatory effect of phosphatidylethanolamine on N-acylphosphatidylethanolamine-
hydrolyzing phospholipase D (NAPE-PLD). 
22 Leung, D. et al.; Biochemistry, 45, 2006, 4720-4726. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms 
for the biosynthesis of endocannabinoids. 
23 Simon, G.M. et al.;  J. Biol. Chem., 281, 2006, 26465-26472. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine 
and a role for alpha/beta-hydrolase 4 in this pathway. 
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In particular, the action of GDE1 is higher for C16:0, C18:1, C20:4, which are the substrates least 
affected by NAPE-PLD activity24. 
Another pathway passes through the action of phospholipase C (PLC) that releases 6hosphor-N-
arachidonoyl ethanolamine (pAEA) from NAPE; the following cleavage by phosphatase protein 
tyrosine phosphatase (PTPN22) leads to the formation of AEA25. 
The characterization of at least three important pathways through which NAEs are synthesized poses 
questions about the selectivity of action of each one.  
Depending on the acyl chain, the phospholipid membrane composition at the site of synthesis and the 
tissue conditions, one pathway would be preferred over the others leading to different NAEs; for 
example, the opposite regulation of NAPE-PLD and PTPN22 expression in macrophages under LPS 
(lipopolysaccharide) stimulation suggests that PTPN22 is responsible for activity-dependent AEA 
production rather than NAPE-PLD26. 
Moreover, the block of a synthetic pathway would be compensate by the increased activation of 
another one, leading to different levels for each NAE27. 
                                                          
24 Simon, G.M. et al.; J. Biol. Chem., 283, 2008, 9341-9349. Anandamide biosynthesis catalyzed by the phosphodiesterase GDE1 and detection of 
glycerophospho-N-acyl ethanolamine precursors in mouse brain. 
25 Liu, J. et al.; Neuropharmacology, 54, 2008, 1-7. Multiple pathways involved in the biosynthesis of anandamide.  
26 Liu, J. et al.; Proc. Natl. Acad. Sci. USA, 103, 2006, 13345-13350. A biosynthetic pathway for anandamide.  
27 Sun, Y. X. et al.; Biochem. J., 380, 2004, 749-756. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase 
A2 and lysophospholipase D.  
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Scheme 1: AEA and other NAEs biosynthesis 
 
1.1.2 Endocannabinoid signalling via 2-arachidonoylglycerol  
2-arachidonoylglycerol (2-AG) is an endogenous cannabinoid receptor ligand, which binds to both 
central and peripheral cannabinoid receptors, eliciting a variety of cannabinergic responses in vitro 
and in vivo. 
2-AG functions as a retrograde synaptic neurotransmitter modulating both inhibitory GABAergic and 
excitatory glutamatergic signaling, it is more abundant than AEA in the brain and it is considered the 
main endocannabinoid signalling molecule.  
As shown for NAEs, different synthetic pathways are responsible for the production of 2-AG (scheme 
2); the first and more direct one gives 2-AG by the action of a classic lipase, cleaving the residues in 
position 1 and 3 of a triacylglycerol containing the arachidonic acid in position 2.  
Another mechanism passes from a two steps pathway, via generation of sn-1-acyl-2-
arachidonoylglycerol (DAG) from phosphatidylinositol (PI) by PLC activity and subsequent 
hydrolysis of the produced DAG by a diacylglycerol lipase (sn-1-DAG lipase)28. It has been 
                                                          
28 Stella, N. et al.; Nature, 388, 1997, 773-778. A second endogenous cannabinoid that modulates long-term potentiation.  
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demonstrated that cellular activity of these two enzymes highly correlates with 2-AG production, and 
their inhibition results in the decreasing of this endocannabinoid mediator29. 
DAG can be obtained from phosphatidic acid (PI) by the action of phosphatidic acid 
phosphohydrolase (PA-phosphohydrolase), which is an alternative pathway than the PLC one30.  
The third biosynthetic route passes through the sn-1-lysophospholipid (lyso-PI) which, with the 
subsequent action of phospholipase A1 (PLA1) and lysophosphatidylinositol-selective phospholipase 
C (lyso-PLC) gives 2-AG31. 
It is important to keep in mind that most of these mediators are intermediates of different pathways, 
and not all of them are involved in the physiological cannabinoid signalling process. 
Moreover, the synthesis of 2-AG seems to be related to different stimuli, and it is connected to the 
activation of the different synthetic pathways.  
 
Scheme 2: 2-AG biosynthesis 
  
                                                          
29 Bisogno, T. et al.; J. Cell Biol., 163, 2003, 463-468. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of 
endocannabinoid signaling in the brain. 
30 Bisogno, T. et al.;  J. Neurochem., 72, 1999, 2113-2119. Phosphatidic acid as the biosynthetic precursor of the endocannabinoid 2-
arachidonoylglycerol in intact mouse neuroblastoma cells stimulated with ionomycin. 
31 Ueda, H. et al.; J. Neurochem., 61, 1993, 1874-1881. A possible pathway of phosphoinositide metabolism through EDTA-insensitive phospholipase 
A1 followed by lysophosphoinositide-specific phospholipase C in rat brain. 
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1.1.3 Endocannabinoids release 
The biosynthesis occurring after the arrival of the appropriate stimuli is immediately followed by the 
release of Ecs in the synaptic space, through a mechanism that is not completely clear but that seems 
to be mediated by the action of an “endocannabinoid membrane transporter” (EMT), responsible also 
for the internalisation at the level of the presynaptic cell. 
This idea is supported by different observations:  
- loading cells with radiolabelled AEA leads to the release of the compound with a temperature-
dependent mechanism which is possible to inhibit pharmacologically32; 
- selective inhibitors of AEA cellular uptake can inhibit the release of de novo synthesised AEA, 
with increase of post-synaptic intracellular AEA levels33. 
                                                          
32 Hillard, C. J. Et al.; J Neurochem, 69, 1997, 631-638. Accumulation of N arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs 
via facilitated diffusion.  
33 Ligresti, A. et al.; Biochem J, 380, 2004, 265-272. Further evidence for the existence of a specific process for the membrane transport of anandamide. 
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1.2 Cannabinoid receptors CB1/CB2 and retrograde mechanism of Ecs 
A great advancement in the understanding of the endocannabinoid system was made in the 90’s, with 
the discovery of the endogenous target on which cannabis sativa‘s extract worked. 
In a very short period, two different type of receptors were identified and described: the CB1 and CB2 
receptors. 
Endocannabinoids act, by definition, on these two receptors that are the physiological target for their 
activity; obviously, they have different affinities and efficacy: 
- AEA and NADA are more selective for the CB1 type, with the following order of affinities 
AEA > NADA; 
- AEA is a partial agonist on CB1 and is almost inactive on CB234; 
- 2-AG has almost the same affinity for both types of receptors and acts as a full agonist on 
both35; 
- Virhodamine is an antagonist for CB1 and a partial agonist for CB236; 
Other non-CB receptors responding to high level of endocannabinoids – and of AEA in particular – 
were identified: 
- vanillyl fatty acid amide receptors37, isolated in murine astrocytes; 
- AEA/abnormal cannabidiol receptor38, another GPCR rec. for AEA and the non-psychotropic 
cannabinoid identified in vascular endothelial cells, which mediate the local vasodilating 
effect of AEA;  
- saturated NAE-receptors39, proposed to mediate some of the analgesic and anti-inflammatory 
effects of PEA; 
- vanilloid TRPV1 receptor40, site of action of capsaicin (component of pungent red pepper) 
activated by the action of AEA and NADA; 
- peroxisome proliferator-activated receptor (PPAR), in particular PPARα, mediates the 
analgesic effect of PEA41, and other types are bound by AEA and 2-AG42. 
                                                          
34 McAllister, S. D. et al.; Prostaglandins Leukot Essent Fatty Acids, 66, 2002, 161-171. CB(1) and CB(2) receptor mediated signalling: a focus on 
endocannabinoids.  
35 Di Marzo, V. et al.; Prostaglandins Leukot Essent Fatty Acids, 53, 1995, 1-11. Anandamide, an endogenous cannabinomimetic eicosanoid: ’killing 
two birds with one stone’.  
36 Porter, A. C. et al.; J Pharmacol Exp Ther, 301, 2002, 1020-1024. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity 
at the CB1 receptor.  
37 Sagan, S. et al.; Eur J Neurosci, 11, 1999, 691-699. Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors 
distinct from CB1 cannabinoid receptors in cultured astrocytes. 
38 Jarai, Z. et al.; Proc. Natl. Acad. Sci. USA, 96, 1999, 14136-14141. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct 
from CB1 or CB2 receptors.  
39 Franklin, A. et al.;  J Neurosci, 23, 2003, 7767-7775. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell 
motility. 
40 Szallasi, A. et al.;Pharmacol Rev, 51, 1999, 159-212. Vanilloid (Capsaicin) receptors and mechanisms.  
41 Sun, Y. et al.; Br J Pharmacol., 152 (5), 2007; 734-743. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism.  
42 Lenman, A. et al.; Br J Pharmacol., 151 (8), 2007; 1343–1351. Interaction of ligands for the peroxisome proliferator-activated receptor gamma with 
the endocannabinoid system.  
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Both CB1 and CB2 receptors are G-protein coupled receptors, that share little sequence homology, 
44% at the protein level or 68% in the transmembrane domains – which are thought to contain the 
binding sites for the Ecs43. 
As anticipated, Ecs action mechanism is realised through a retrograde signalling: the depolarisation 
of the post-synaptic neuron caused by Ca2+ influx produces the activation of the biosynthetic ways 
and the formation/liberation of the endocannabinoids; the newly synthesised Ecs travel in the synaptic 
space, bind the pre-synaptic CB receptors and operate with an inhibitory effect on transmitters’ 
release.  
CB receptors couple to the adenylate cyclase through Gi/o subtypes of G-proteins, and that causes – 
after ligand binding – the block of cyclase activity, the reduction of calcium influx and the decrease 
of transmitters vesicles’ release.  
The receptors couple also to the system of phosphatidylinositol-3-phosphate kinase, which take a role 
as second messenger in addition to the adenylate cyclase system. 
Overall, this chain of events leads to a temporary or more persistent dimming of inhibitory currents 
at GABAergic and of excitatory currents glutamatergic synapsis respectively44. 
The different effects observed in the endocannabinoid system are related to the type of ligand, the 
receptor activated and the tissue localisation, which is a fundamental parameter for the understanding 
of the system and of the possible druggability.  
 
1.2.1 CB1 receptors 
In general, CB1 are highly expressed throughout the brain by many classes of neurons, and in lower 
level are present in glia cells and many peripheral cell lines45; they are abundantly expressed in 
GABAergic interneurons and less in glutamatergic principal neurons46. 
CB1 couple to Gi/o proteins and modulate the activity of different ion channels and second messenger, 
and the different modulation of cell functions depends by their acute versus sustained activation47. 
For example, neuronal CB1 receptors acute activation (milliseconds or seconds) inhibits pre-synaptic 
N-type Ca2+-channels and activate K+-channels reducing neurotransmission and controlling 
excitability48.  
                                                          
43 Marsicano, G. et al.; Nature, 418, 2002, 530-534. The endogenous cannabinoid system controls extinction of aversive memories. 
44 Rhee, M. H: et al.; J. Neurochem., 71 (4), 1998, 1525-1534. Cannabinoid Receptor Activation Differentially Regulates the Various Adenylyl Cyclase 
Isozymes. 
45 Howlett, A. C. et al.; Pharmacol Rev., 54, 2002; 161-202. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors.  
46 Uchigashima, M. et al.; J Neurosci., 27(14), 2007; 3663-3676.  Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated 
retrograde signaling and its physiological contribution to synaptic modulation in the striatum. 
47 Straiker, A. et al.; AAPS J., 8 (2), 2006; 272-276. Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years.  
48 Marinelli, S. et al.; Nat Neurosci., 12(12), 2009; 1488–1490. Self-modulation of neocortical pyramidal neurons by endocannabinoids.  
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CB1 sustained activation (minutes or hours) results on the other hand, in the stimulation of 
intracellular signalling, such through ERK, modifying the activity of enzymes and the expression of 
specific genes49.  
 
1.2.2 CB2 receptors 
CB2 receptors display a different pharmacological profile and tissue localisation than the CB1 type
50. 
They are not expressed in healthy brain tissue, with exceptions of a small neurons’ population in the 
brain stem and in the cerebellum51; furthermore, CB2 receptors expression can be induced in many 
immune cells thus, in particular conditions of neuroinflammation, these receptors could be up-
regulated by specific cell populations in the brain52. 
CB2 receptors population is typical of immune system cells, and was identified in different immune 
subpopulations with the following ranking related to the expression level: B-cells, natural killer cells, 
monocytes, neutrophils, CD8 T-cells, CD4 T-cells, tonsils, spleen, thymus cells53. 
With this distribution, it is easy to understand the importance of CB2 receptors for what concerns 
immune system functions, the role that can be played by the ECS in inflammation processes and 
responses to infections and cancers. 
  
                                                          
49 Marsicano, G. et al.; Science, 302, 2003, 84-88. CB1 cannabinoid receptors and on-demand defense against excitotoxicity.  
50 Felder, C. C. et al.; Mol Pharmacol., 48 (3), 1995, 443-450. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 
and CB2 receptors.  
51 Van Sickle, M. D. et al.; Science, 310 (5746), 2005; 329-332. Identification and functional characterization of brainstem cannabinoid CB2 receptors. 
52 Nunez, E. et al.; Synapse, 53 (4), 2004; 208-213. Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an 
immunohistochemical study.  
53 Galiegue, S. et al.; Eur. J. Biochem., 232, 1995, 54-61. Expression of central and peripheral cannabinoid receptors in human immune tissues and 
leukocyte subpopulations.  
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1.3 Endocannabinoids degradation 
Once released in the extracellular space (fig. 3), Ecs act prevalently – with varying selectivity – on 
cannabinoid receptors (CB1 and CB2); however, AEA and NADA can also act – previously to their 
release – on intracellular sites, such the vanilloid TRPV1 (transient receptor potential vanilloid type 
1) ion channels, or T-type Ca2+ ion channels. In these cases, their release in the extracellular 
compartment seems to be a way to inactivate the action of these endocannabinoids, rather than to 
facilitate their action. 
 
Fig. 3: Synaptic junction (from Current Medicinal Chemistry 17 (24), 2010) 
The fate of Ecs is strictly correlated to their reuptake by the pre-synaptic and the post-synaptic cells. 
In fact, after the action on CB receptors their activity is rapidly terminated by the internalisation in 
the cells, followed by their hydrolytic inactivation by the deputed enzymes: the Fatty acid amide 
hydrolase (FAAH), the Monoacylglycerol lipase (MAGL) and the N-acyl ethanolamine-hydrolysing 
acid amidase (NAAA). 
It has been demonstrated that, when incubated with intact cells, the Ecs are rapidly cleared away from 
the extracellular medium54; as previously said, this process depends on the presence of a membrane 
transporter (EMT) which is responsible for the uptake of the Ecs from the extracellular to the 
intracellular spaces. 
The evidence that the process is saturable, sensitive to temperature, selective for polyunsaturated 
long-chain fatty acid derivatives and sensitive to inhibitors, supports the hypothesis55  
                                                          
54 Di Marzo, V. et al.; Nature, 372, 1994, 686-691. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. 
55 Beltramo, M. et al; Neuroreport, 11, 2000, 1231-1235. Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-
arachidonylglycerol. 
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However, the high lipophilic nature of the Ecs seems to be responsible for their natural reuptake, 
mediated by a passive diffusion mechanism driven by the intracellular enzymatic activity, which 
maintains the gradient between the inside and the outside of the cell56. 
Taken together, these data suggest that, even if the intracellular hydrolysis has a great influence on 
the rate of Ecs facilitated diffusion, the existence of an EMT – subjected to regulation – is fundamental 
for the fate of the endocannabinoids57; in fact, their reuptake is immediately followed by the 
inactivation by the hydrolytic enzymes, which bring the stop signal to the system.  
It is important to remember that in addition to the enzymes strictly correlated to the endocannabinoid 
system (MAGL, FAAH, NAAA), the presence of long-chain polyunsaturated fatty acid derivatives 
calls in also other enzymes. 
Most of all, part of the Ecs degradation is related to the action of cyclooxygenase-2 (COX-2).  
 
Fig. 4: Possible Ecs degradation pathways (from Trends in pharmacological sciences, 35, 2014) 
In fact, as shown in fig. 4, the production of arachidonic acid (AA) from the Ecs hydrolysing enzymes, 
leads to the liberation of great amounts of this mediator, which can enter its classical cascade for the 
synthesis of prostaglandins, leukotrienes and thromboxanes58.  
  
                                                          
56 Deutsch, D. G. et al.; J Biol Chem , 276, 2001, 6967-6973. The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide 
hydrolase. 
57 Glaser, S. T. et al.; Proc. Natl. Acad. Sci. USA, 100, 2003, 4269-4274. Evidence against the presence of an anandamide transporter.  
58 Alhouayek, M. et al.; Trends Pharmacol. Sci, 35 (6), 2014, 1925-1938. COX 2-derived  endocannabinoid metabolites  as  novel  inflammatory 
mediators 
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1.3.1 Fatty Acid Amide Hydrolase  
 
Scheme 3: AEA hydrolysis by FAAH 
The Fatty acid amide hydrolase (FAAH) is the enzyme responsible for the cleavage and inactivation 
of AEA (scheme 3). 
The action spectra of the enzyme is wider than this; in fact, in addition to AEA it can hydrolase a 
small amount of 2-AG, PEA and other NAEs59. 
Furthermore, its localisation is specifically post-synaptic, and for this reason, the degradation of AEA 
occurs at the level of the post-synaptic cell, requiring the intervention of the endocannabinoid 
membrane transporter to internalise the endogenous ligand60. 
FAAH is an integral membrane enzyme that seems to be able to organise in oligomers at membrane 
level, forming an over-structure that is necessary to take interaction with its substrates60; the enzyme 
crystallises in a dimeric structure, indicating that it is at least a dimer in solution61. 
Its intricate membrane binding structure may facilitate the movement of its substrates directly from 
the bilayer to the active site – which is directed toward the intracellular compartment – without the 
need of transporting these substrates through the aqueous cytosol, but thanks to the existence of 
different channels in the FAAH structure61.  
These channels grant the enzyme simultaneous access to both the membrane and the cytoplasmic 
compartments of the cell; at least three channels have been described to be important in substrates 
recruitment and recognition62, and one of those has amphipathic features in order to manage both the 
hydrophobic long acid chains and the hydrophilic head groups 
In this model, after substrates’ entrance through the membrane to the active site, and following 
hydrolysis, the liberated fatty acid (hydrophobic) and amine (hydrophilic) products would exit 
through the membrane-access and cytosolic-access channels, respectively.  
The cytoplasmic channel is needed also to provide the entry of a water molecule that is required for 
deacylation of the FAA-FAAH acyl-enzyme intermediate63. 
                                                          
59 Cravatt, B.F, et al.; Nature., 384 (6604), 1996, 83-87. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. 
60 Patricelli, M. P. et al.; Biochemistry,37(43), 1998, 15177-15187. Comparative Characterization of a Wild Type and Transmembrane Domain-Deleted 
Fatty Acid Amide Hydrolase:  Identification of the Transmembrane Domain as a Site for Oligomerization. 
61 Bracey, M.H. et al.; Science, 15, 2002, 1793-1796. Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. 
62 Cravatt, F.et al.; Biochemistry, 40 (20), 2001 6107-6115. Characterization and Manipulation of the Acyl Chain Selectivity of Fatty Acid Amide 
Hydrolase. 
63 Patricelli, M.P. et al.; Biochemistry, 38 (43), 1999, 14125-14130. Fatty Acid Amide Hydrolase Competitively Degrades Bioactive Amides and Esters 
through a Nonconventional Catalytic Mechanism. 
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FAAH belongs to the α/β serine-hydrolase superfamily, and its catalytic mechanism is very similar 
to that of this class but, instead of a classical serine-hystidine-aspartic acid catalytic triad, Lys-142 
appears to play as both a base and acid in the hydrolytic mechanism (fig. 6)64. 
Fig. 5: FAAH’s catalytic triad (from Annu. Rev. Biochem. 74, 2005) 
This residue activates nucleophilic Ser-241 for the attack on the substrate 
carbonyl function , and then seems to participate in the protonation of the 
substrate’s leaving group64; the process is helped somehow by the presence 
of another serine residue (in particular Ser-217), the lack of which produces 
a high reduction in the catalytic capability65. 
This particular Ser-Ser-Lys catalytic triad (fig. 5), with the double action of 
the Lys-142, justifies the ability of FAAH to hydrolyse at the same rate 
amides and esters substrates, because of the protonation process induced by the presence of this 
residue.  
 
Fig. 6: Hydrolytic mechanism of FAAH 
The subsequent intervention of a water molecule completes the hydrolysis with the detachment of the 
acyl chain from the enzyme. 
The impact of Lys-142 on Ser-241 nucleophile strength and leaving group protonation likely occurs 
indirectly via the bridging Ser-217 of the triad, which may act as a “proton shuttle”64. 
The understanding of the molecular features of FAAH and of its catabolic mechanism, helped in the 
design of different classes of compounds, with the aim of synthesising inhibitors of this enzyme that 
is implied in several physiological and pathological conditions. 
 
1.3.2 N-Acylethanolamine-hydrolysing Acid Amidase  
In contrast to polyunsaturated NAEs, saturated and monounsaturated NAEs appear to be inactive at 
cannabinoid receptors.  
                                                          
64 Patricelli, M.P. et al.; Biochemistry, 38 (31), 1999, 9804-9812. Chemical and Mutagenic Investigations of Fatty Acid Amide Hydrolase:  Evidence for 
a Family of Serine Hydrolases with Distinct Catalytic Properties. 
65 McKinney, M. K. Et al.; J. Biol. Chem., 278, 2003, 37393-37399. Evidence for Distinct Roles in Catalysis for Residues of the Serine-Serine-Lysine 
Catalytic Triad of Fatty Acid Amide Hydrolase. 
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However, these NAEs show different biological activities: PEA is anti-inflammatory66, 
immunosuppressive67, neuroprotective68, and analgesic69.  
Furthermore, OEA is anorexic70, and SEA is pro-apoptotic71 and anorexic72; all these activities are 
mediated by the action on different receptors: PPAR73, GPR-5574. 
All these molecules are catabolised for a very small amount by FAAH, and for the major part by an 
enzyme that has been named NAAA: N-acylethanolamine-hydrolysing acid amidase75. 
NAAA does not reveal sequence homology with FAAH and belongs to another class of hydrolase; 
its predominant characteristic is the catalytic optimum at pH 4.5 – 5, which is consistent with its 
localisation at lysosomes level. 
Another particularity is that NAAA exhibits ~35% homology to the structure of acid ceramidase, the 
lysosomal enzyme responsible for the hydrolysis of ceramide to fatty acid and sphingosine. 
Moreover, the catalytic centre of human NAAA contains Cys-126 and Asp-145, and it is very 
interesting to note that this cysteine residue corresponds to Cys-143 of human acid ceramidase, 
confirming the homology between the two enzymes76. 
FAAH and NAAA show several differences in the catalytic properties, which suggest their different 
roles in vivo. 
The most important difference, as said, is the pH dependency of their catalytic activities: FAAH is 
active in a wide range of pH with the optimal pH value at 8.5 – 10, while NAAA shows a pH optimum 
at 4.5 – 5 and is almost inactive at alkaline pH and even at neutral pH77. 
The cellular localisation of NAAA is consistent with its acidic optimum of pH 4-5, which is the 
normal pH of the intralysosomal compartment, and their substrate preferences are different too, with 
FAAH preferring AEA and NAAA preferring all other NAEs78. 
Thus, NAAA is more similar to acid ceramidase than FAAH, but is strictly related to the catabolism 
of different atypical endocannabinoids such as NAEs.  
                                                          
66 Facci, L. t al.; Proc. Natl. Acad. Sci. USA, 92, 1995, 3376-3380. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to 
anandamide and palmitoylethanolamide. 
67 Berdyshev, E. v. et al.; Eur. J. Pharmacol., 330, 1997, 231-239 Influence of fatty acid ethanolamides and Δ9-tetrahydrocannabinol on cytokine and 
arachidonate release by mononuclear cells. 
68 Skaper, S. D. et al.; Proc. Natl. Acad. Sci. USA, 93, 1996, 3984-3989. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, 
are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. 
69.Calignano, A. et al.; Eur. J. Pharmacol., 419, 2001, 191-198. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. 
70 Rodriguez de Fonseca, F. et al.; Nature, 414, 2001, 209-212. An anorexic lipid mediator regulated by feeding. 
71 Maccarrone, M. et al.; Biochem. J., 366, 2002, 137-144. Binfind, degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells. 
72 Terrazzino, S. et al.; FASEB J., 18, 2004, 1580-1582. Stearoylethanolamide exerts anorexic effects in mice via down-regulation of liver stearoyl-
coenzyme A desaturase-1 mRNA expression. 
73 Fu, J. Et al.; Nature, 425, 2003, 90-93. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. 
74 Baker, D. et al.; Trends Pharmacol. Sci., 27, 2006, 1-4. In silico patent searching reveals a new cannabinoid receptor. 
75 Tsuboia, K. Et al.; CHEMISTRY & BIODIVERSITY, 4, 2007, 1914-1925. The N-Acylethanolamine-Hydrolyzing Acid Amidase (NAAA). 
76.Bernardo, K. Et  al.; J. Biol. Chem., 270, 1995, 11098-11102. Purification, characterization, and biosynthesis of human acid ceramidase. 
77 Tsuboi, K. Et al.; J. Biol. Chem., 280, 2005, 11082-11092. Molecular Characterization of N-Acylethanolamine-hydrolyzing Acid Amidase, a Novel 
Member of the Choloylglycine Hydrolase Family with Structural and Functional Similarity to Acid Ceramidase. 
78 Ueda, N. et al.; J. Biol. Chem., 270, 1995, 23823-23827. Partial Purification and Characterization of the Porcine Brain Enzyme Hydrolyzing and 
Synthesizing Anandamide. 
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1.3.3 Monoacylglycerol Lipase  
A special role in the endocannabinoid system functioning is played by 2-arachidonoyl glycerol; 
anyway, its activity has to be blocked after its action on the appropriate target, to avoid the over 
activation that is typical of direct agonists/antagonists use. 
The termination of 2-AG signalling occurs intracellularly by an enzyme called Monoacylglycerol 
Lipase (MAGL)79, which acts hydrolysing the molecule of 2-AG to free arachidonic acid and glycerol 
(scheme 4) after the transport from the extracellular space. 
 
Scheme 4: 2-AG hydrolysis by MAGL 
MAGL was purified in 1975 from rat-adipocyte tissue, its molecular weight was estimated to be 32.9 
kDa and it was found to work best at a pH 8.080; the enzyme specifically catalyses the hydrolysis of 
monoacylglycerols and is unable to operate the same reaction on either di- or tri-acyl glycerols.  
Interestingly, MAGL has no effect on AEA levels, while FAAH is able to catalyze the breakdown of 
2-AG. 
The inhibition of this enzyme leads to higher 2-AG levels in the brain and therefore holds significant 
therapeutic potential; it was studied in depth and described to be involved in a very wide range of 
physiological and pathological conditions81. 
For these reasons, the interest around MAGL has spread out and the synthesis of active molecules 
able to act at this level of the endocannabinoid system has become more and more interesting, opening 
the field to different pharmacological approaches for MAGL modulation. 
Detailed information about MAGL will be given in chapter two. 
  
                                                          
79 Somma Delpero, C. et al.; Biochem. J., 312, 1995, 519-525. Purification and properties of a monoacylglycerol lipase in human erythrocytes. 
80 Tornqvist, H. et al.; J. Biol. Chem., 251, 1976, 813-819. Purification and some properties of a monoacylglycerol-hydrolyzing enzyme of rat adipose 
tissue. 
81 Fowler C. J. Et al.; Br. J. Pharmacol., 166, 2012, 1568-1585. Monoacylglycerol lipase - a target for drugdevelopment? 
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1.4 Role of ECS in disease 
The ubiquity of ECS poses the necessity to study in depth every component of this system to 
understand each specific role; the quantification of anandamide and 2-AG levels in various tissues 
under physiological and pathological conditions provided important information as to the possible 
functions of these mediators. 
Ecs are abundant in the brain, particularly in the basal ganglia and cerebellum where they control 
movement and posture82; their actions on autonomic nervous system result in the regulation of 
circulatory and gastrointestinal functions83 and the hypothalamic-pituitary-adrenal axis – underlying 
their role on reproduction)84, bone formation85 and adipocyte functioning86. 
Ecs signalling often undergoes dramatic tissue-specific changes in pathological conditions87; in many 
cases, Ecs levels are controlled through various mechanism that often differ between AEA and 2-AG 
and are the reflection of different role of FAAH and MAGL enzymes88. 
There are also examples of the same stimulus (e.g. leptin) leading to the same change in the tissue 
concentrations of AEA and 2-AG, but through different regulatory strategies and it is also known that 
the levels Ecs precursors are influenced by the diet and by its relative contents in arachidonic and 
docosahexaenoic acids. 
During some acute pathological states or temporary perturbations of the normal homeostasis of the 
organism, the levels of at least one EC in the tissues specifically involved in the disorder are 
momentarily elevated to help re-establish the normal levels of other endogenous mediators. 
It can happen for example in specific nervous system areas following insults or stress stimuli (food 
deprivation, aversive memories, pain, and head injury)89 
The progressive nature of some disorders might results in a permanent over activation of the system; 
this is an initial help to re-establish the homeostasis, but could be traduced in the development of 
symptoms typical of the disorder. 
It happens in experimental model of Parkinson’s disease, in which Ecs levels are elevated in the 
attempt to reduce glutamatergic and GABAergic signalling, but end up contributing to locomotor 
impairment viaCB1 receptors90. 
                                                          
82 Van der Stelt, M. et al.; Eur. J. Pharmacol., 480, 2003, 133-150. The endocannabinoid system in the basal ganglia and in the mesolimbic reward 
system: implications for neurological and psychiatric disorders. 
83 Lynch, M. E. et al.; Pain Res Manag, 10, 2005; 7-14. Preclinical science regarding cannabinoids as analgesics: An overview. 
84 Barna, I. et al.; Life Sci., 75, 2004; 2959-2970. The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo 
and in vitro studies in CB1 receptor knockout mice. 
85 Tam, J. et al.; Mol Pharmacol, 70, 2006, 786-792. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone 
remodeling. 
86 Walter, L. et al.; Br. J. Pharmacol., 141, 2004; 775-785. Cannabinoids and neuroinflammation. 
87 Van der Stelt, M. et al.; Cell Mol Life Sci, 63, 2006, 1410-1424. .; Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of 
pharmacological elevation of endocannabinoid levels. 
88 Witting, A. et al.; Proc. Natl. Acad. Sci. USA, 101, 2004, 3214-3219. P2X7 receptors control 2-arachidonoylglycerol production by microglial cells. 
89 Di Marzo, V. et al.; Annu Rev Med ,57, 2006, 553-574. Plant, synthetic, and endogenous cannabinoids in medicine. 
90 Fernandez-Espejo, E. et al.;. Neurobiol Dis, 18, 2005; 591-601. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very 
severe nigral lesion in experimental parkinsonism. 
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Similarly, in Alzheimer’s disease models, Ecs protects from microglial cell-driven inflammation but 
they also participate in CB1-mediated loss of memory, with particular implication of AEA in this 
process91. 
Also in lateral sclerosis animal models, elevated level of Ecs in the spinal cord seems to induce 
protective effects that are mediated by CB2 receptors
92. 
A lot more studies have been made to fully understand the role of ECS in physiology and pathology, 
and to underlie the possible pharmacological interventions that can be made. 
  
                                                          
91 Ramirez, B. G. et al.; J Neurosci, 25, 2005, 1904-1913. Prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection mediated by 
blockade of microglial activation. 
92 Bilsland, L. G. et al.; FASEB J, 20, 2006, 1003-1005. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease 
progression in SOD1 mice. 
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2. MONOACYLGLYCEROL LIPASE BIOCHEMICAL CHARACTERISATION 
 2.1 Molecular characterization and structure features 
Twenty years after its discovery, MAGL was cloned from a mouse-adipocyte cDNA library and it 
was determined to be composed by 302 amino acids93; later, the cloning of the human MAGL 
analogue was made, founding to contain 303 residues94. 
The homology’s degree in terms of amino acids sequence between mouse-, rat- and human isoforms 
is very high, with human and mouse MAGL identical for 84%, rat and mouse MAGL identical for 
92%95. 
MAGL shows no homology with FAAH or other known amidases, but shares a similar tertiary fold 
that is typical of many lipases - the α/β-hydrolase fold96. 
Enhancements in MAGL structure comprehension were made when the enzyme was crystallised in 
2010 by Lambert et al97 and the structure resolved by X-ray diffraction. 
MAGL was found to organise as a biological dimer, and that data was confirmed by another 
experiment performed by mass spectrometry, in which no monomer’s peak was found after gel 
filtration chromatography. 
Furthermore, similarly to what reported after the elucidation of FAAH structure98, it was found that 
both catalytic site entries face the same direction, and are oriented in the best way to interact with the 
membrane for recruiting the substrate. 
The enzyme structure presents the features of the α/β-hydrolase superfamily: its central β-sheet is 
constituted of seven parallel and one antiparallel strands and is surrounded by six α-helices; a cap 
domain (which varies much more among the members) covers the β-sheet and the active site. 
Buried in depth below the cap there is the catalytic triad, composed by residues Ser-122, Asp-239, 
His-269 and closely superimposed on that of other hydrolases. 
Ser-122 is located in the GXSXG consensus sequence between helix-α3 and strand-β5, in the so-
called “nucleophilic elbow” sharp turn found within this superfamily; the oxyanion hole is constituted 
by backbone NH from Ala-51 and Met-123 and stabilizes the tetrahedral anionic intermediate during 
hydrolysis (as for Lys-142 in FAAH structure during AEA hydrolysis). 
                                                          
93 Karlsson, M. et al.; J. Biol. Chem., 272, 1997, 27218-27223. cDNA Cloning, Tissue Distribution, and Identification of the Catalytic Triad of 
Monoglyceride Lipase. 
94 Dinh, T.P. et al.; Proc. Natl. Acad. Sci. USA, 99, 2002, 10819-10824. Brain monoglyceride lipase participating in endocannabinoid inactivation. 
95 Karlsson, M. et al.; Gene, 272, 2001, 11-18. Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene. 
96 T. P. Dinh, T. F. Freund, D. Piomelli,Chem. Phys. Lipids2002, 121, 149-158 A role for monoglyceride lipase in 2-arachidonoylglycerol inactivation 
97 Labar, G. et al.; ChemBioChem, 11, 2010, 218-227. Crystal Structure of the Human Monoacylglycerol Lipase, a Key Actor in Endocannabinoid 
Signaling. 
98 Bracey, M. H. et al.; Science, 298, 2002, 298, 1793-1796. Structural Adaptations in a Membrane Enzyme That Terminates Endocannabinoid Signaling. 
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The homology of MAGL to other different enzymes used as model is quite high for what concerns 
the central core structure and the catalytic triad99, but it changes significantly considering the cap 
domain (from residue 151 to 225) and substrate binding site.  
In fact, in MAGL the cap domain varies substantially: in the upper part a first α-helix is moved 
outward then in model enzymes; in the lower part, a longer loop connects α-5 to α-6 helices. 
Through these modifications, the four helices pass from a V-shaped organisation (typical of esterases 
and haloperoxidases) to a wider U-shaped structure, allowing the enzyme to give substrates a broader 
access to the active site, comparing to other related proteins. 
This particular organisation is responsible for substrate recruitment and access to the catalytic site 
and for the action on different ECs. 
Furthermore, it is useful to mention that MAGL - contrary to FAAH that is a post-synaptic 
membrane’s enzyme - was reported to be present both in the cytosolic and in the membranes fractions 
of pre-synaptic cells (immunohistochemical studies indicate that MAGL is often co-localized with 
the CB1 cannabinoid receptor, predominantly on the axon terminals of pre-synaptic neurons
100). 
 
 2.2 Catalytic mechanism, substrate specificity and tissue distribution 
The characteristic action of MAGL is the hydrolysis of EC molecule 2-AG; the recruitment of the 
substrate and the catabolic mechanism are strictly related to the structural features of the enzyme, and 
in particular of the cap domain, the active site and the exit pores for final products. 
Docking studies of 2-AG to MAGL showed the formation of a tetrahedral intermediate (fig. 7) 
covalently bound to Ser-122 (as for FAAH mechanism). 
Fig. 7: MAGL’s catalytic site (from ChemBioChem 11, 
2010) 
These studies revealed a cavity (wider and wider moving 
away from the catalytic triad) able to accommodate the long 
and flexible lipid chain of the substrates; several 
hydrophobic residues cover the channel leading from the 
surface to the nucleophilic serine. 
Leu-148, Ala-164, Leu-176, Ile-179, Leu-205, Val-207, Ile-211, Leu-213, Leu-214, Val-217 and 
Leu-241 side chains are properly located to interact with the arachidonoyl moiety of 2-AG, and 
mediate the MAGL substrate specificity for lipid substrates. 
                                                          
99 Roussel, A. et al.; J. Biol. Chem., 277, 2002, 2266-2274. Crystal Structure of the Open Form of Dog Gastric Lipase in Complex with a Phosphonate 
Inhibitor. 
100 Gulyas, A. I. et al.; Eur. J. Neurosci., 20, 2004, 441-458. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic 
compartments in the rat hippocampus, cerebellum and amygdala. 
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The catalytic environment on the contrary presents a more hydrophilic character: the Tyr-58 hydroxyl 
group, the NH from the His-121 and His-272 side chains, the guanidinium from Arg-57, the 
carboxylate from Glu-53, and the backbone carbonyl from Ala-51 delimit a polar cavity that 
accommodates the polar glycerol head group of 2-AG. 
MAGL was reported to hydrolyse 1-OG and 2-OG at similar rates101, and docking of 2-AG allows to 
understand this lack of selectivity; in fact, if the acyl chain is bound in the 2-position, the glycerol 
moiety does not entirely fill up the hydrophilic cavity. 
Therefore, the glycerol group of 1-OG can freely be accommodated in the same pocket without 
encountering a steric hindrance, and stretches to the bottom of the cavity. 
A small opening coated by Pro-178, Ser-181, Leu-184, Tyr-194, Asn-195, Arg-202 and Ala-203, 
connects the active site to the outside of the protein; this channel, perpendicular to the path from the 
hydrophilic pocket to the membrane binding site is the exit door for the glycerol moiety that is 
released after the action of the enzyme. 
All these molecular observations constitute the logical explanation to the characteristic selectivity of 
MAGL for its different possible substrate, with the undisputed action on monoacylglycerol 
derivatives over their di- or tri- substituted analogues, but without the possibility to have a clear 
preference between sn-1 and sn-2-substituted derivatives. 
In addition, the preferences for different types of acid chains are very wide, with the enzyme able to 
act on a variegated pool of acyl chains; the only prerequisite is that the acid has to be unsaturated. 
MAGL can hydrolyse medium- and long-chain fatty acids: myristic, palmitic, oleic, stearic, and 
arachidonic acid, from the sn-2-position of the monoacylglycerol with the highest hydrolysis rate 
observed for arachidonic acid102. 
The first localisation of MAGL was made in the adipose tissue, but from that moment it has extended 
to many other tissues and now it is known that the enzyme is ubiquitous. 
In rat it is present in adipose tissue, testis, kidneys, adrenal gland, brain, liver, skeletal muscle, ovary 
and spleen103; the presence of MAGL at brain’s level is ubiquitous to, and it is expressed in the cortex, 
hippocampus, cerebellum, thalamus, striatum and in lower amount in the brainstem and 
hypothalamus104. 
                                                          
101 Tornqvist, H. et al.; J. Biol. Chem., 251, 1976, 813-819. Identification and some characteristics of the enzyme protein of the hormone-sensitive 
lipase from rat adipose tissue. 
102 Rindlisbacher, B. et al.; Biochim. Biophys. Acta, 905, 1987, 349-357. Diacylglycerol breakdown in plasma membranes of bovine chromaffin cells is 
a two-step mechanism mediated by a diacylglycerol lipase and a monoacylglycerol lipase. 
103 Karlsson, M. et al.; Gene, 272, 2001, 11-18. Exon-intron organization and chromosomal localization of the mouse monoglyceride lipase gene. 
104 Gulyas, A. I. et al.; Eur. J. Neurosci., 20, 2004, 441-458. Segregation of two endocannabinoidhydrolyzing enzymes into pre- and postsynaptic 
compartments in  the rat hippocampus, cerebellum and amygdala. 
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In many tissues, the cellular distribution of MAGL was reported both in the membrane and in the 
cytosol: in fact, microsomal and membrane fractions of human platelets possess MAGL activity105, 
in the intestinal mucosa it is associated with the microsomal and the mitochondrial fractions106 and 
the same happens for pancreas β-cells, chromaffin cells and erythrocytes107. 
 
 2.3 MAGL inhibitors 
Since the discovery of MAGL and the understanding of its relations in many physiological and 
pathological conditions, a lot was made to develop molecules that could act on this enzyme. 
In particular the research is focused on the study of MAGL inhibitors, molecules that act blocking 
the catalytic activity of the enzyme, causing a local increase in the levels of 2-AG and thus, producing 
a pharmacological effect which could targeted to a specific region of the body and not producing a 
general activation of the endocannabinoid system. 
In fact, one of the major concern with the development of molecules working on the ECS is that they 
could produce cannabis-like effects - catalepsy, hypothermia, hyperphagia - which would limit their 
therapeutic use. 
When the first selective FAAH inhibitor was discovered and showed no induction of the cannabinoid-
tetrad (thermal analgesia, catalepsy, locomotor activity and rectal temperature)108, this concern was 
greatly reduced, pushing researchers to go deeper inside the field of endocannabinoid enzyme 
inhibition. 
As for FAAH, also for MAGL there is the need to find potent ad selective inhibitors; the first 
generation MAGL inhibitors (fig. 8) showed modest activity in vivo, but were initially used to 
indicate that MAGL was a 2-AG hydrolase and that its block caused the increase in brain 2-AG levels 
in animal models. 
                                                          
105 Prescott, S. M. et al.; J. Biol. Chem., 258, 1983, 764-769. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an 
arachidonoyl-monoacylglycerol intermediate. 
106 Senior, J. R. et al.; J. Clin. Invest., 42, 1963, 187-192. Utilization of Glycerol-C14 for Intestinal Glyceride Esterification: Studies in a Patient with 
Chyluria. 
107 Somma-Delpero, C. et al.; Biochem. J., 313, 1995, 519-525. Purification and properties of a monoacylglycerol lipase in human erythrocytes. 
108 Kathuria, S. et al.; Nat. Med., 9, 2003, 76-81. Modulation of anxiety through blockade of anandamide hydrolysis. 
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Fig. 8: Examples of MAGL inhibitors 
MAGL activity can be attenuated by general non-specific serine hydrolase inhibitors such as methyl 
arachidonoylfluorophosphonate, phenylmethnsulfonyl fluoride, arachidonoyl trifluoromethylketone 
and hexadecyl sulfonyl fluoride109. 
The first selective MAGL inhibitors URB602, N-archidonoyl maleimide (NAM) and OMDM-169 
had modest increase in 2-AG concentration and proved to be effective against rodent model of pain. 
 
  2.3.1 Carbamate compounds 
URB602 was the first MAGL-preferring inhibitor to be reported110; it elevates 2-AG levels without 
altering that of AEA and mediate peripherally anti-nociceptive  effects in various models of pain111. 
The action of URB602 is exerted with a non-competitive, partially reversible mechanism of action 
and the inhibition is time-independent112. 
From this molecule, many derivatives were synthesised maintaining the structural carbamate core and 
varying in different ways the side rings and chains: isosteric replacement, incorporation of biphenyl 
element, insertion of p-substituent groups led to the conclusion that the carbamate functionality is a 
promising scaffold for the development of MAGL inhibitors.  
 
  2.3.2 JZL184 and other inhibitors targeting the catalytic site 
In 2009, the piperidine carbamate JZL184 (fig. 9) was discovered113: it blocks MAGL with very high 
potency (IC50 of 8nM) and shows a huge in vivo increase in 2-AG levels in the brain.  
                                                          
109 Saario, S. M. et al.; Biochem. Pharmacol., 67, 2004, 1381-1387. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-
arachidonoylglycerol in rat cerebellar membranes. 
110 Hohmann, A. G. et al.; Nature, 435, 2005, 1108-1112. An endocannabinoid mechanism for stress-induced analgesia. 
111 Desroches, J. et al.; Br. J. Pharmacol., 155, 2008, 913-924. Modulation of the antinociceptive effects of 2-arachidonoyl glycerol by peripherally 
administered FAAH and MGL inhibitors in a neuropathic pain model.  
112 King, A.R. et al.; Chem. Biol., 14, 2007, 1357-1365. URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol 
degradation in intact brain slices. 
113 Long, J. Z. et al.;5, Nat. Chem. Biol., 2009, 37-44. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.  
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It works through the formation of a covalent complex with the nucleophilic Ser-122114 with results in 
the irreversible deactivation of the enzyme; the selectivity for MAGL is very high compared to that 
on FAAH but it blocks many other carboxylesterases in peripheral tissues, cross reactivity for FAAH 
after repeated administration and low cross-species activity.  
The acute administration of this compound seemed to be positively effective, but the repeated 
administration caused many negative results: CB1-receptor desensitisation, cross-tolerance to 
receptor agonist and tolerance to their anti-nociceptive effects, physical dependence115. 
Trying to overcome cross-species activity, new compound with O-hexafluoroisopropyl carbamate116 
or N-hydroxysuccinimidyl carbamate functionalities have been studied117. 
 
 
Fig. 9: Catalytic site-targeting inhibitors 
The resulting compound KML29118 (fig.9) showed very good selectivity for MAGL, with inhibitory 
values comparable to that of JZL184; moreover, it showed inhibitory activity both on rat and human 
MAGL, improving  cross-species activity.  
The bad side of the KML29 is that it causes cannabimimetic effects when administered in vivo119. 
Another promising compound is SAR127303120, a potent O-hexafluoroisopropyl carbamate (fig.9): 
it shows potent inhibitory activity on mouse and human MAGL, and good selectivity for MAGL over 
FAAH; it exerts anti-nociceptive effects in inflammatory and visceral pain models and anti-epileptic 
effects, but it also negatively affects memory formation, causes impairment in cognitive 
performances. 
                                                          
114 Long, J.Z. et al.; Chem. Biol., 16, 2009, 744-753. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral 
endocannabinoid metabolism. 
115 Schlosburg, J. E. et al.; Nat. Neurosci., 13, 2010, 1113-1119. Chronic monoacylglycerol lipase blockade causes functional antagonism of the 
endocannabinoid system. 
116 Chang, J. W. et al.; Chem. Biol., 19, 2012, 579-588. Highly selective inhibitors of monoacylglycerol lipase bearing a reactive group that is bioisosteric 
with endocannabinoid substrates. 
117 Niphakis, M. J. et al.; ACS Chem.Neurosci., 4, 2013, 1322-1332. Evaluation of NHS carbamates as a potent and selective class of endocannabinoid 
hydrolase inhibitors.  
118 Chang, J. W. et al.; ACS Chem. Biol.8, 2013, 1590-1615. Proteome-wide reactivity profiling identifies diverse carbamate chemotypes tuned for 
serine hydrolase inhibition.  
119 Pasquarelli, N. et al.; Neuropharmacology, 91, 2015, 148-156. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor 
KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue. 
120 Griebel, G. et al.; Sci. Rep., 5, 2015, 7642-7670. Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning 
and memory performance while producing antinociceptive activity in rodents. 
27 
 
Some other serine-reactive compounds have been described121 but beside the good potency on MAGL 
they lack of selectivity for this enzyme. 
 
  2.3.3 Cysteine-targeting compounds 
MAGL is sensitive to sulfhydryl-specific inhibitors, such mercuric chloride, 4-chloromercuribenzoic 
acid and N-ethylmaleimide, all molecules that act oxidising the –SH residues of Cys-201 and Cys-
242, which are known to be in their reduced form for the maintaining of enzyme’s activity122. 
Starting from the evidence that MAGL contains some sensitive sulfhydryl sensitive sites, different 
N-ethylmaleimide derivatives were tested as potential MAGL inhibitors123 and with the aim of 
understanding the role of these –SH containing residues. 
 
Fig. 10: N-arachidonylmaleimide 
In this way, NAM (fig. 10) was identified as the most potent compound targeting MAGL cysteines124; 
the action of this class of compounds is exerted with a Michael addition mechanism, which results in 
the formation of a covalent adduct between the enzyme and the compound, causing an irreversible 
inhibition125. 
 
 
  2.3.4 Disulphide compounds 
Various disulphide compounds were tested to fully understand the role of cysteine residues, including 
disulfiram analogues - dicyclopentamethylenthiuram disulphide (fig. 11) and phenyl disulphide126. 
                                                          
121 Ortar, G. et al.; Eur. J. Med. Chem., 63, 2013, 118-130. Biaryl tetrazolyl ureas as inhibitors of endocannabinoid metabolism: modulation at the N-
portion and distal phenyl ring. 
122 Scalvini, L. et al.; Chem. Phys. Lipids, 2015, Monoglyceride lipase: Structure and inhibitors. 
123 Saario, S. M. et al.; Chem. Biol., 12, 2005, 649-656. Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-
arachidonoyl-glycerol in rat cerebellar membranes. 
124 Matuszak, N. et al.; J. Med. Chem.,  52, 2009, 7410-7420. Synthesis and in vivo evaluation of N-substituted maleimide derivatives as selective 
monoglyceride lipase inhibitors. 
125 Zvonok, N. et al.; Chem. Biol., 15, 2008, 854-862. Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the 
catalytic site by mass spectrometry and mutational analysis. 
126 Labar, G. et al.;, ChemBioChem, 8, 2007, 1293-1297. Disulfiram is an inhibitor of human purified monoacylglycerol lipase, the enzyme regulating 2-
arachidonoylglycerol signalling. 
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Fig. 11: Example of a disulphide compound 
The activity of these compounds is comparable to that of carbamate compounds and their activity is 
made possible through a redox process requiring the formation of a mixed disulphide with Cys-208 
and Cys-242. 
The use of reducing agents reversed the inhibition127, supporting the hypothesis that the role of these 
cysteine residues is fundamental for the activity of the enzyme and could be a potential target for 
MAGL inhibitors development. 
 
  2.3.5 Natural terpenoids 
Some natural compounds proved to be active as MAGL inhibitors: pristimerin and euphol128 (fig. 12). 
These two molecules belongs to the terpenoid class and showed good activity on MAGL; pristimerine 
can react with cysteine groups giving covalent adduct through a reversible non-competitive 
mechanism. 
Euphol showed to be less potent than pristimerin but with a similar mechanism. 
 
Fig. 12: Natural terpenoids 
The effect of these two molecules resulted in an increased level of 2-AG, without effects on those of 
AEA. 
More recently, the pentacyclic terpenoid β-amyrin was discovered as a novel MAGL inhibitor129 with 
no effect on the other endocannabinoid system’s enzymes; an important observation was that this 
compound could block also the action of two other 2-AG hydrolysing enzymes - ABHD6 and 
                                                          
127 Kapanda, C. N. et al.; J. Med. Chem., 52, 2009, 7310-7314. Bis(dialkylaminethiocarbonyl)disulfides as potent and selective monoglyceridelipase 
inhibitors. 
128 King, A. R. et al.; Chem. Biol., 16, 2008, 1045-1052. Discovery of potent and reversible monoacylglycerol lipase inhibitors. 
129 Chicca, A. et al.; Br. J. Pharmacol., 167, 2012, 1596-1608. The antinociceptive triterpene amyrin inhibits 2-arachidonoylglycerol (2-AG) hydrolysis 
without directly targeting cannabinoid receptors. 
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ABHD12 - confirming terpenoids as a promising class of natural compounds for the regulation of 2-
AG levels. 
 
 2.4 Therapeutic potential of MAGL-metabolizing enzymes inhibitors 
As previously said, the endocannabinoid system - and the MAGL in particular - are ubiquitously 
expressed in the body; this fact, taken together with the proved participation of the catabolic enzymes 
in a lot of physiological ad pathological conditions, open the field for the development of hydrolysis’ 
inhibitors that can have a therapeutic potential. 
The fields of application can be very wide, because of the implications of the ECS in a wide range of 
systems (fig. 13): from the cardiovascular system, to immune system, from the gastrointestinal to the 
reproductive system; moreover, there is a great interest in the role of ECS in pain and inflammation, 
cognitive functions and cancer development and therapy. 
 
Fig. 13: ECS ubiquity (from British Journal of Pharmacology, 166, 2012) 
For all these systems, the implication of the ECS was studied and described in depth, and a lot of 
experimental evidences suggested that the block of the catabolic hydrolysis can be the right way to 
search treatments concerning endocannabinoid dysfunctions, more than the use of direct receptor 
agonists or antagonists.  
In the following paragraphs, the role of MAGL inhibition will be discussed relatively to its 
implication in different systems, as examples of the therapeutic possibilities related to the use of 
synthetic compounds active on MAGL. 
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  2.4.1 In inflammation 
A very big deal for MAGL inhibitors possible application is their use in inflammatory and 
neurodegenerative diseases. 
Different studies have shown that MAGL is the primary source of arachidonic acid for the generation 
of pro-inflammatory eicosanoids in many tissues, including the brain, the liver and the lungs130, thus 
its block could be a potential therapeutic strategy. 
MAGL blockade proved to reduce mechanical allodynia in mice undergoing sciatic nerves chronic 
constriction131 and to be protective in mouse model of inflammatory bowel disease, in which the use 
of a selective MAGL inhibitor reduced inflammatory cytokine levels and restored the intestinal 
barrier functions132. 
Chronic MAGL blockade prevented also chronic stress-induced anxiety-like behaviour and long-term 
depression of GABAergic transmission, preventing the synaptic adaptation to chronic stress that may 
cause to the worsening of the affective disorders133. 
Pharmacological and genetic ablation of the enzyme showed anti-inflammatory effects in Parkinson’s 
and Alzheimer’s disease mouse models134 and protected from pharmacological-induced 
dopaminergic neurodegeneration135; a recent study136 showed that MAGL blockade caused the 
lowering of β-amyloid plaque levels in Alzheimer’s disease lowering also eicosanoids’ levels. 
These positive effects on Alzheimer’s disease are sustained by the observation that MAGL block 
caused a reduction in the cleavage of Amyloid Precursor Protein (APP), responsible for the formation 
of aggregating peptides Aβ1-40 and 1-42. 
It was also shown that the use of MAGL inhibitors reduced neurodegeneration, maintained the 
integrity of hippocampal synaptic structure and function and improved long-term synaptic plasticity 
and memory in Alzheimer’s disease models. 
Concerning peripheral tissue injuries, different studies have shown the positive effects of MAGL 
blockade in this situation: MAGL inactivation lowered hepatic inflammation caused by ischemia-
reperfusion injury by lowering neutrophil infiltration, inflammatory cytokines, and reactive oxygen 
stress137. 
                                                          
130 Nomura, D. K. Et al.; Science, 334, 2011, 809-813. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. 
131 Kinsey, S. G. et al.; J. Pharmacol. Exp. Ther., 330, 2009, 902-910. Blockade of Endocannabinoid-Degrading Enzymes Attenuates Neuropathic Pain. 
132 Alhouayek, M. et al.; FASEB J., 25, 2011, 2711-2721. Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic 
inflammation. 
133 Sumislawski, J. J. et al.; 36, 2011, 2750-2761. Reversible Gating of Endocannabinoid Plasticity in the Amygdala by Chronic Stress: A Potential Role 
for Monoacylglycerol Lipase Inhibition in the Prevention of Stress-Induced Behavioral Adaptation. 
134 Piro, J. R. et al.; Cell Rep., 1, 2012, 617-623. Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of 
Alzheimer's Disease. 
135 Long, J. Z. et al.; Chem. Biol., 16, 2009, 744-753. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral 
endocannabinoid metabolism. 
136 Chen, R. Q. et al.; Cell Rep., 2, 2012, 1329-1339. Monoacylglycerol lipase is a new therapeutic target for Alzheimer’s disease. 
137 Cao, Z. et al.; Gastroenterology, 144, 2013, 808-817. Monoacylglycerol Lipase Controls Endocannabinoid and Eicosanoid Signaling and Hepatic 
Injury in Mice. 
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Another study showed that MAGL inhibitors could protect against lung injury in a 
lipopolysaccharide-induced lung injury model; the acute treatment with an inhibitor reduced 
leukocytes migration into the lungs, vascular permeability and inflammatory chemokine levels in 
alveolar fluids138. 
 
  2.4.2 In pain 
MAGL inhibitors can have therapeutic applications in the field of pain treatment, but for their use 
some preliminary facts have to be taken into consideration:  
- the pain state has to respond to cannabinoid agonists, to confirm that the situation could at 
least respond to the ECS signalling; 
- animal models have to prove that in the studied situation the ECS is out of balance, so that the 
block of MAGL can have a measurable effect, either to normalise a deficient signal or to 
potentiate a protective response; 
- for repeated dose regimes, there should be no tolerance to the compound in question. 
Positive effects have been described: several clinical trials were conducted139, and led to the 
conclusion that there are evidences that cannabinoids are safe and effective in neuropathic pain, with 
efficacy in fibromyalgia and rheumatoid arthritis140. 
Detectable levels of AEA and 2-AG were found in synovial fluid from patient with osteoarthritis and 
rheumatoid arthritis undergoing total knee surgery against no detectable levels in normal people141. 
In all these studies, the use of MAGL inhibitors was investigated, leading to the conclusion that they 
can be useful for the treatment of residual pain after certain types of surgery (amputations, 
thoracotomy, mastectomy, coronary artery bypass)142. 
It was demonstrated that after surgery, there is an increase in the relative proportion of MAGL-
positive cells, pointing to a disturbance of the EC system following surgery, in which the use of 
MAGL inhibitors could be a potential help143. 
Alkaitis et al144 indicated that “there are suggestions that therapeutic strategies designed to enhance 
endocannabinoid signalling may prevent patients from developing persistent or chronic pain states 
                                                          
138 Costola-de-Souza, C. et al.; PLoS One, 8, 2013, 525-532. Monoacylglycerol lipase (MAGL) inhibition attenuates acute lung injury in mice. 
139 Campbell, F. et al.; Br. Med. J., 323, 2001, 13-16. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative 
systematic review. 
140 Lynch, M. E. et al.; Br. J. Clin. Pharmacol., 72, 2011, 735-744. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of 
randomized trials. 
141 Richardson, D. et al.; Arthritis Res. Ther., 10, 2008, R43. Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients 
with osteoarthritis and rheumatoid arthritis. 
142 Kehlet, H. et l.; Lancet, 367, 2006, 1618-1625. Persistent postsurgical pain: risk factors and prevention. 
143 Ma, W. X. Et al.; Int. J. Legal. Med., 125, 2011, 549-558. Time-dependent expression and distribution of monoacylglycerol lipase during the skin-
incised wound healing in mice.  
144 Alkaitis, M. S. et al.; PLoS ONE, 5, 2010, 398-409. Evidence for a role of endocannabinoids, astrocytes and p38 phosphorylation in the resolution of 
postoperative pain. 
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following surgery”; this conclusion resulted in the validation of the hypothesis that MAGL inhibitors’ 
use could have positive effects on pain treatment. 
 
2.4.3 In cancer and cancer treatment 
One of the most interesting possible application of MAGL inhibitors is in cancer treatment. 
In fact, tumour cells adapt their metabolism toward a lipogenic phenotype, which is related to high 
expression of MAGL, a key element in the fatty acid network145. 
The high expression of this enzyme - able to liberate fatty acid chains from their precursors - offers 
to cancer cells the possibility to find highly energetic molecules with which feed their expensive 
replicative machinery. 
This is a fundamental process for energy generation during deprivation and an essential source of 
precursors for lipids and membrane synthesis, or lipid signalling mediators146. 
The dysregulated lipogenesis seems to play a key role in cancer development and progression because 
tumour cells can use the lipolytic pathway to generate essential lipid blocks for their accelerated 
metabolism and proliferation. 
The recent availability of MAGL inhibitors helped to prove that MAGL is highly expressed in 
different types of human cancer cell; moreover, MAGL activity also correlates with high 
proliferation, invasiveness and tumour growth147. 
MAGL is elevated, for example, in colon carcinoma and in androgen-independent prostate cancer 
cells148; its tumour-promoting action is due to the degradation of substrates different from 2-AG and 
the liberation of other free fatty acids, in particular C16:0 and C18:1149 that enter in a tumorigenic 
network sustained by their conversion in oncogenic lipid mediators. 
In prostate cancer, the antitumor effects of MAGL block are completely abolished by co-treatment 
with fatty acids, indicating that increased endocannabinoid signalling and a reduced supply of free 
fatty acids from MAGL contribute to the antitumor effect. 
Furthermore, MAGL blockade can be also a strategy for alleviating cancer-associated symptoms: in 
fact, 2-AG administration and MAGL inhibition attenuate nausea and vomiting and reduce 
mechanical hyperalgesia in bone cancer pain150. 
                                                          
145 Pisanti, S. et al.; Trends in Pharmacol. Sci., 34 (5), 2013, 273-282. The endocannabinoid signaling system in cancer. 
146 Lass, A. et al.; Prog. Lipid Res., 50, 2011, 14-27. Lipolysis - a highly regulated multi-enzymecomplex mediates the catabolism of cellular fat stores. 
147 Nomura, D. K. et al.; Cell,  140, 2010, 49-61. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. 
148 Ye, L. et al.; Cancer Lett., 307, 2011, 6-17. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. 
149 Nomura, D. K. et al.; Chem. Biol., 18, 2011, 846-856. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to 
support prostate cancer. 
150 Khasabova, I. A. et al.; Pharmacol. Res., 64, 2011, 60-67. Increasing 2-arachidonoyl glycerol signaling in the periphery attenuates mechanical 
hyperalgesia in a model of bone cancer pain. 
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On the other hand, brain tumours, such as gliomas, are related to increased endocannabinoid tone and 
the use of MAGL inhibitors would be detrimental. 
All these observations confirm cancer treatment as an interesting field of application for MAGL 
inhibitors, but a lot more has to be done, both in the development of potent drugs and in the 
identification of the appropriate diseases on which their use could be positive. 
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1. AIMS OF THE WORK 
The real comprehension of the endocannabinoid system - of the role of its endogenous substrates, 
synthetic and degrading enzymes, receptors and implications in health and diseases - is a major task 
for the implied scientists151. 
To understand the mechanisms at the base of this system, and how to act in order to develop possible 
treatments for different pathological situations, it is necessary to have access to easy and reliable 
methods for the evaluation of potential drugs’ use. 
Moreover, trying to explore the different mechanisms involved in the ECS, and how modulate them, 
there is the need of different types of active molecules, which can help in the understanding of the 
general situation and could be potential therapeutic agents. 
 
The aims of this work are: 
- the developing of a fast and reliable fluorescence method for activity screening of potential 
inhibitors; 
- the design and synthesis of new molecules able to act as MAGL (which is our main target) 
inhibitors; 
- the evaluation of new synthetic molecules’ activity through our self-developed fluorescence 
method. 
 
The purpose of this work then is to add a piece in the knowledge of the ECS, and to identify some 
potentially active compounds, which could be selected for the improvement of therapeutic 
interactions with this complex - but still very fascinating - system. 
  
                                                          
151 Piomelli, D. et al.; Neuropharmacology, 76, 2014, 228-234. More surprises lying ahead. The endocannabinoids keep us guessing. 
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2. SET UP OF A NEW FLUORESCENCE-BASED ASSAY FOR MAGL INHIBITORS 
SCREENING 
One of the major task in the development of MAGL inhibitors remains the necessity of a fast and 
reliable method for the evaluation of potentially active compounds, to speed up the process that runs 
through the design of a new molecule and its evaluation as an active agent on the endocannabinoid 
system. 
At the moment, different methods are described for the evaluation of potential inhibitors’ activity, on 
the isolated enzyme or in in vitro assays.  
These methods are based on the evaluation of a signal (light at different wavelengths, in particular) 
that is released when the enzyme hydrolyses a suitable substrate; that signal is then recorded and 
correlated to the amount of transformed substrate basing on a calibration curve and the value obtained 
associated to the activity of MAGL. 
Each of these methods, however, has several different features in terms of specificity, sensitivity and 
time and simplicity of analysis. 
- p-nitrophenyl alkyl derivatives: 
One of the first assay described for in vitro evaluation of potential MAGL inhibitors, used p-
nitrophenyl-alkyl derivatives152 as chromogenic substrate: in particular the use of p-nitrophenyl 
acetate subjected to the action of MAGL led to the liberation of acetate and a molecule of p-
nitrophenol (scheme 5) which is detectable at 405 nm by an UV-Vis spectrophotometer. 
 
Scheme 5: Liberation of p-nitrophenol 
This method is very easy to apply, having the advantages of using cheap reagents and a common 
instrumentation (the UV-Vis spectrophotometer); unfortunately, its specificity is very low, because 
p-nitrophenyl alkyl derivative can be hydrolysed by different lipases, due to their ability to work on 
and hydrolyse the simple ester bond typical of this class of compounds153. 
- 2-AG detection by mass spectrometry: 
Another method154 described the measurement of the amount of free arachidonic acid liberated by 2-
AG after the action of MAGL, with an HPLC/mass spectrometry technique. 
                                                          
152 Muccioli, G. G.; ChemBioChem, 9, 2008, 2704-2710. CAY10499, a Novel Monoglyceride Lipase Inhibitor Evidenced by an Expeditious MGL Assay. 
153 Salameh, M. A. et al.; Appl. Environ. Microbiol., 73 (23), 2007, 7725-7731. Purification and Characterization of Two Highly Thermophilic Alkaline 
Lipases from Thermosyntropha lipolytica. 
154 King, A. R. et al.; Br. J. Pharmacol. 157, 2009, 974-983. A critical cysteine residue in monoacylglycerol lipase is targeted by a new class of 
isothiazolinone-based enzyme inhibitors. 
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The specificity of this method is the highest among the known methods due to the measurement of 
the natural substrate, but it needs the use of a very expensive instrument (such as the mass 
spectrometer) and the set-up of the assay, which can be a long process, thus not suitable for a rapid 
screening. 
- Glycer-2-yl-4-pyrenylbutanoate: 
A third method described the use of glycer-2-yl-4-pyrenylbutanoate as MAGL substrate155. 
Similarly to the UV-based method, the enzyme works on the substrate leading to the liberation of a 
molecule of glycerol and one of 4-pyrenylbutanoic acid, molecule which can be detected by 
fluorescence (λex.340 nm/λem.380 nm) (scheme 6). 
 
Scheme 6: Liberation of 4-pyrenylbutanoic acid 
The advantages of this method are that the sensitivity of the fluorescence detector is higher than that 
of the UV one, and the glyceric scaffold makes the substrate more similar to the endogenous 2-AG, 
increasing the specificity versus the p-nitrophenyl alkyl method. Unlikely there are issues that have 
to be taken in consideration: in fact the native substrate glycer-2-yl-4-pyrenylbutanoate is detectable 
itself at the same wavelengths used for its metabolite 4-pyrenylbutanoic acid, so an HPLC separation 
is needed to distinguish the two different molecules. 
This situation leads to the necessity to use a HPLC apparatus with fluorescence detector, in order to 
quantify the free form of 4-pyrenylbutanoic acid from its precursor, thus implying to search for the 
appropriate working conditions on each instrument (flow, time, etc.) and to build a calibration curve 
which - in HPLC technics - means the use of lot of time, solvents etc. 
- [3H]2-arachidonoyl glycerol: 
Some assays shown the use of a tritiated derivate156 of 2-AG (or 2-OG) such, for example [3H]2-AG 
(scheme 7). 
The method is based on the separation of the tritiated arachidonic acid by its precursor and the 
measurement of the radioactivity by scintillation. 
The specificity and sensitivity are very good because of the use of the natural substrate and the high 
responsiveness of the radioactive signal, but it requires the handling of radioactive materials - which 
                                                          
155 Holtfrerich, A. et al.; Anal Biochem, 399, 2010, 218-224. High-performance liquid chromatography assay with fluorescence detection for the 
evaluation of inhibitors against human recombinant monoacylglycerol lipase. 
156 Matuszak, N. et al.; J. Med. Chem., 52, 2009, 7410-7420. Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective 
monoglyceride lipase inhibitors. 
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need specific instrumentations, procedures and people trained to use this kind of substances - and for 
these reasons not widely available. 
 
Scheme 7: Liberation of tritiated arachidonic acid 
- Use of fluorogenic probe: 
The last method157 is based on the use of a fluorogenic probe, in particular 7-arachidonoyl-4-methyl-
coumarin (7-HCA). 
This method differs from the one using glycer-2-yl-4-pyrenylbutanoate because 7-HCA is not 
fluorescent itself, but once subjected to the enzyme’s action, it leads to the liberation of a fluorescent 
molecule of 7-hydroxmethyl coumarin (7-HC), which shows a signal detectable by a fluorimeter with 
λex.370 nm/λem.450 nm (scheme 8). 
 
Scheme 8: Liberation of fluorescent 7-HC 
The advantage of this method is that, thanks to the non-fluorescent precursor transformed in a 
fluorescent derivative by the action of MAGL, it is possible to obtain a value which is directly relative 
to the action of the enzyme (only converting the fluorescence signals through a calibration curve) 
without the necessity of sample treatments and separations. 
                                                          
157 Savinainen, J. R. et al.; Anal Biochem, 399, 2010, 132-134. Characterization of binding properties of monoglyceride lipase inhibitors by a versatile 
fluorescence-based technique. 
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For this reason the method is very fast, simple, and cheap; on the other hand, even if it is particularly 
potent for a rapid screening of potential inhibitors on pure MAGL, it has to be taken into account that 
interactions with other hydrolases using cell preparations are possible. 
Moreover, cellular samples excited at 370 nm show a quite high background noise derived by the 
intrinsic fluorescence of tryptophan residues, and it could be a potential source of disturbance.  
In addition, the assay emits blue fluorescence, which can significantly enhance interference due to 
compound fluorescence and dust or lint, all of which fluoresce in the blue wavelength region158. 
All the methodics have positive and negative aspects and features, in terms of costs, specificity, 
sensitivity or interferences; the choice has to be made basing on the type of screening needed, and the 
research for an assay that can be a good compromise is still going on. 
                                                          
158 Fritzsche, M. et al.; Anal Bioanal Chem, 398, 2010, 181-191. Fluorescent cell-based sensing approaches for toxicity testing. 
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 2.1 Design of new fluorogenic probe 7-hydroxyresorufinylarachidonate 
We decided to synthesise a new fluorogenic probe, which could overcome the problem of auto 
fluorescence of cell culture assays, which are the focus of inhibitors studies. 
The idea was based on the use of a fluorogenic probe - which is not fluorescent by itself - that releases 
a high fluorescent molecule after the action of MAGL. 
Fig. 14: Structure of resorufin 
In the pool of potential fluorophores our choice fell on resorufin 
(fig.14): this molecule is highly fluorescent159 at pH 7.4 (which is 
typical of this kind of assay) and has λex.370 nm/λem.450 nm that are 
out of the field of auto fluorescence of cell cultures158. 
The fluorescence emission is due to the deprotonated anion of resorufin, since its pKa value is 
relatively lower than pH 5-6160. 
 
Scheme. 9: Hydrolysis of 7-HRA by MAGL 
We synthesised a new long-wavelength fluorogenic substrate, 7-hydroxyresorufinyl-arachidonate (7-
HRA), a highly convenient fluorogenic probe with high signal-to-noise ratio, excellent stability 
against non-specific degradation and which can be a useful tool in further development of MAGL 
inhibitors (scheme 9). 
The new substrate was synthesised and tested to verify its stability in different conditions; it was then 
used for the set up and the validation of a new fluorescent assay for MAGL inhibitors screening and 
afterwards used for testing different synthetic molecules that were prepared in the laboratory. 
  
                                                          
159 Myung, G. C. et al.; Org. Lett., 12 (24), 2010, 37-49. Chromogenic and Fluorogenic Signaling of Sulfite by Selective Deprotection of Resorufin 
Levulinate. 
160 Simpson, D. J. et al.; J. Org. Chem., 56, 1991, 5391-5396. A Mechanism-Based Fluorogenic Probe for the Cytochrome P-450 Cholesterol Side Chain 
Cleavage Enzyme. 
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 2.2 Synthesis of 7-HRA 
New fluorogenic probe 7-HRA was synthesised expressly to be used in the fluorescence based 
method for the evaluation of MAGL activity and with the purpose of obtaining a fast and reliable 
method for potential inhibitors screening. 
The synthesis was carried out in a two steps classical coupling reaction161 as shown in scheme 10: 
the starting arachidonic acid was dissolved in dry CH2Cl2 (one drop of DMF added) and activated 
through the addition of oxalyl chloride at 0°C; after the necessary period of time (3h) for the 
activation, the solvent was evaporated and the residual arachidonoyl chloride dissolved in dry CH2Cl2. 
This solution was added dropwise to an ice-cold suspension of resorufin in dry CH2Cl2/triethylamine, 
and stirred overnight at room temperature. 
 
Scheme 10: Synthesis of 7-HRA 
The suspension was diluted with CH2Cl2 and filtered for the removal of the salts.  
The liquid residue was subsequently washed with 1M HCl and saturated NaHCO3, dried on anhydrous 
sodium sulfate and purified by column chromatography on silica gel, giving the red oil product 7-
HRA (62%). 
  
                                                          
161 Mulvihill, M. M. et al.; Life Sciences, 92, 2013, 506-511. Therapeutic potential of monoacylglycerol lipase inhibitors. 
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 2.3 Method set up 
- Substrate stability: 
7-HRA proved to be stable for at least 6 months stored at -18°C in the dark, and dissolved (10 μM) 
in DMSO without TLC-noticeable decomposition. 
The stability of substrate 7-HRA was tested in three different buffer solutions: 50 mM Tris–HCl (pH 
7.4, 1 mM EDTA), 0.5 M Hepes (pH 7.4), and phosphate-buffered saline (PBS, pH 7.4).  
To 90 μl of the selected buffer with 5 μl of DMSO, 7-HRA (10 mM in DMSO) was added, reaching 
the final concentration of 10 μM; after the incubation period of 3 h (darkness, room temperature), the 
fluorescence signal was measured at 588 nm (λex.571 nm/λem.588 nm) by Promega-Glomax 
multidetection system. 
 
Buffer Resorufin liberation (%) 
Tris-HCl 2.3 % 
Hepes 2.1 % 
PBS 2.3 % 
Tab. 1: Resorufin liberation in three different buffers 
As shown in tab. 2, Tris–HCl buffer led to the liberation of 2.3 % of total available resorufin, Hepes 
buffer 2.1 %, and PBS 2.3 %; the previous use of Tris–HCl buffer for our preliminary studies and the 
comparable results among the three different buffers, led us to continue to use Tris-HCl for further 
experiments. 
pH 7.4 was selected for the fluorescence MAGL assay to facilitate the comparison with previous data 
and because typically, biochemical assays are performed near the physiological pH in attempt to 
mimic the intracellular environment of the natural enzyme.  
To ensure solubility of the hydrophobic substrate 7-HRA the addition of 10 % DMSO in test solutions 
was made, since human recombinant MAGL preserves its activity up to that concentration162; the 
solubility of the substrate under these conditions appeared to be excellent, allowing to follow the 
reaction over many hours without precipitation’s problems.  
 
- Kinetics of 7-HRA hydrolysis by hMAGL: 
For the setup of kinetics experiments and the determination of kinetics parameters, we used the 
commercially available human recombinant enzyme (hMAGL by Cayman Chemical).  
                                                          
162 Wang, Y. et al.; Assay Drug Dev Technol, 6, 2008, 387-393. A fluorescence based assay for monoacylglycerol lipase compatible with inhibitor 
screening. 
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Many papers describes the use of bovine serum albumin (BSA) to prevent the non-specific binding 
of the substrate to the walls of the tubes and assists in its solubility163.  
We decided not to use BSA because it is reported to enhance the fluorescence signal even in the 
absence of enzyme163 and it is not compatible with the assay. 
Different amounts of hMAGL ranging from 10 to 75 ng/well were added in each well (final volume 
100 μl) to various concentrations of 7-HRA (from 0.5 to 25 μM, final concentrations) in 50 mM Tris–
HCl (pH 7.4, 1 mM EDTA) with 10 % (v/v) DMSO.  
The fluorescence was read every 5 min, at room temperature, for a period of 3 h using a Promega- 
GloMax multidetection system.  
 
Sample DMSO  
(μl) 
hMAGL 
 sol. (μl) 
Buffer  
sol. (μl) 
7-HRA  
sol. (μl) 
Inhibitor  
sol. (μl) 
Blank 7-HRA 5 - 90 5 - 
Blank hMAGL 5 10 80 5 - 
Tab. 2: Wells composition  
The fluorescence units were converted to amount of resorufin produced basing on a calibration curve 
(fig. 15) by using standard solutions in DMSO (10 μl of standard in 90 μl of buffer).  
All MAGL assays were performed in triplicate for each substrate concentration. 
 
 
Fig. 15: Calibration curve 
As shown in fig. 16, 7-HRA is very stable without enzyme (triangles), and leads to the liberation of 
a good amount of resorufin with the presence of hMAGL (circles). 
                                                          
163 Savinainen, J. R. et al.; Anal Biochem, 399, 2010, 132-134. Characterization of binding properties of monoglyceride lipase inhibitors by a versatile 
fluorescence-based technique. 
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Fig. 16: 7-HRA hydrolysis with (circles) and without (triangles) MAGL 
The optimal conditions for the determination of kinetic parameters were found to be 25 ng/well of 
MAGL with 5 μM 7-HRA (as used in fig.20); the Michaelis–Menten kinetic parameters were derived 
with Prism software, Version 5.0 (GraphPad, San Diego, CA) producing Km=0.87±0.13 μM and 
Vmax=25.84± 0.88 nmol min−1 mg protein−1 (fig. 17). 
 
 
Fig. 17: Kinetics parameter of hMAGL using 7-HRA 5μM 
7-HRA is particularly convenient for HTS experiments due to its low level of reactivity in the absence 
of enzyme. The reproducibility of the assay was given by the Z′ value of 0.80, that suggests the 
compatibility with HTS. 
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2.4 Method validation with known inhibitors 
The validation of the new fluorescent method that uses 7-HRA as fluorogenic substrate for drug 
discovery screening, was made by studying the effect of three different known MAGL inhibitors - 
URB602164, methyl arachidonyl fluorophosphonate (MAFP)158 and JZL184 (fig. 18)157 - under the 
standard assay conditions with 5 μM 7-HRA as substrate, DMSO as solubilizer and Tris–HCl 
(50mM, pH 7.4, 1 mM EDTA) as reaction buffer. 
 
Fig. 18: Structure of known MAGL inhibitors URB602, MAFP and JZL184 
25 ng/well of hMAGL was dissolved in the assay buffer and added to 80 μl of buffer solution in a 96-
wells black plate; 5 μl of inhibitor solutions at different concentrations in DMSO were added and 
then incubated at room temperature for 60 min. For the “blank 7-HRA” well DMSO alone was added, 
whereas inhibitors were prepared in a range of concentration comparable to that used in literature 
(from nM to over μM). 
After incubation, the reaction was started by the rapid addition of 5 μl of 7-HRA intermediate solution 
to obtain the final concentration of 5 μM, in the final volume of 100 μl.  
 
Sample DMSO  
(μl) 
hMAGL 
 sol. (μl) 
Buffer  
sol. (μl) 
7-HRA  
sol. (μl) 
Inhibitor  
sol. (μl) 
Blank 7-HRA 5 - 90 5 - 
Blank hMAGL 5 10 80 5 - 
Inhibitors - 10 80 5 5 
Tab. 3: Wells composition for blanks and inhibitors samples 
The fluorescent signal was measured at different time points (every 3 minutes) for a period of 1 hour 
and the fluorescence unit converted to amount of resorufin basing on the calibration curve. 
The IC50 values were calculated after 30 minutes and derived from two independent experiments 
performed in triplicate, calculated as nonlinear regressions using sigmoid dose–response setting with 
variable Hill slope by GraphPad Prism 5.0 for Windows. 
  
46 
 
Fig. 19: Inhibition of hMAGL by URB602  
As shown in fig. 19, the IC50 value for the 
inhibition of hMAGL (25ng/well) is 9.1 ± 2.3 
μM, which is in line with data reported in 
literature164 for this first selective MAGL 
inhibitor. 
 
 
 
 
 
Fig. 20: Inhibition of hMAGL by MAFP 
As already known methyl arachidonyl 
fluorophosphonate has the lowest IC50 value 
of 5.4 ± 1.7 nM (fig. 20), showing a very high 
inhibitory potential on hMAGL, which is due 
to an irreversible and non-selective 
mechanism of action that prevents its 
application in therapy158. 
 
 
 
 
At last, JZL184 has IC50 value of 217 ± 108 
nM (fig. 21) that matches what observed by 
Savinainen et al157; confirming the good 
activity described for this selective inhibitor. 
 
Fig. 21: Inhibition of hMAGL by JZL184 
 
                                                          
164 Matuszak, N. et al.; J Med Chem, 52, 2009, 7410-7420. Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective 
monoglyceride lipase inhibitors. 
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These results proved that our fluorogenic enzyme assay, using 7-HRA as new fluorogenic substrate - 
and validated with the use of three known inhibitors described in literature - can be successfully 
applied for the identification and activity evaluation of compounds able to modulate MAGL activity. 
Moreover, the red fluorogenic substrate 7-HRA assay proved to be rapid, versatile and compatible 
with high throughput screening and led to the same sensitivity of the blue fluorogenic substrate (7-
HCA), with the advantages of lower interferences on cell culture assays. 
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3. STRUCTURE DESIGN OF NEW POTENTIAL MAGL INHIBITORS 
The beginning of the work was the selection of a reference molecule among the several that are known 
to be MAGL inhibitors165. 
The choice fell on molecule URB602 (fig. 22), which was firstly described in 2005166 as MAGL 
inhibitor. 
 
Fig. 22: URB602 molecule 
Different studies have been made for the evaluation of its activity against MAGL167,168, and other 
works169,170 tried to evaluate which modifications could increase the selectivity and the potency 
against this enzyme. 
In particular, the study of Szabo et al169 showed the importance of different residues in the area 
belonging to the so called “upper active site”, and confirmed the action of URB602 as a non-
covalent inhibitor. 
Fig. 23: Interaction between MAGL and a carbamate inhibitor (from Bioorg. Med. Chem. Lett., 21, 
2011) 
This region is characterised by the presence of a Ser-185 
residue, which can make the formation of hydrogen bond 
interactions possible (fig. 23), with an appropriate substituent 
on the biphenyl side of the structure.  
Always in this area, the presence of different hydrophobic 
residues - such Ala-174, Gly-220 and Leu-186 - suggest the 
formation of hydrophobic interactions with the cycle linked to 
the oxygen side of the carbamate, also suggesting that a 5- to 7-atoms ring could be the best for a 
correct interaction. 
                                                          
165 Fowler, C. J. et al.; Br. J. Pharmacol., 166, 2012, 1568-1585. Monoacylglycerol lipase a target for drug development? 
166Hohmann, A. G. et al.; Nature, 435 (23), 2005, 326-338. An endocannabinoid mechanism for stress-induced analgesia. 
167 King, A. R. et al.; Chem. Biol., 14, 2007, 1357-1365. URB602 Inhibits Monoacylglycerol Lipase and Selectively Blocks 2-Arachidonoylglycerol 
Degradation in Intact Brain Slices. 
168 Comelli, F. et al.; Br. J. Pharmacol., 152, 2007, 787-794. The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and 
anti-nociceptive effect in a murine model of acute inflammation. 
169 Szabo, M. et al.; Bioorg. Med. Chem. Lett., 21, 2011, 6782-6787. The design, synthesis and biological evaluation of novel URB602 analogues as 
potential monoacylglycerol lipase inhibitors. 
170 Tuccinardi, T. et al.; Bioorg. Med. Chem., 22, 2014, 3285-3291. Identification and characterization of a new reversible MAGL inhibitor. 
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The crystallographic structure of MAGL in complex with URB602 showed that a hydrogen bond 
exists between the NH-portion of Asn-162 and the oxygen belonging to the carbamate inhibitor, 
raising the rational for the presence of this peculiar structure.  
Moreover, two other residues - Cys-201 and Cys-208 - were highlighted as very important points for 
the enzyme activity171, and they are considered to be possible targets for inhibitory compounds.  
 
 
Fig. 24: URB602 modification sites 
Taking into account all these considerations, during the design of new molecules (fig. 24), we decided 
to: 
a) maintain the basic carbamate body; 
b) insert very small groups on the biphenyl side, able to increase the possibility of H-bond 
interactions (-F and -CF3 groups); 
c) insert different carbocyclic or aromatic rings linked with variable - but short - spacers to the 
carbamate oxygen, trying to enhance the formation of hydrophobic interactions between the 
candidate drug and the enzyme.  
 
  
                                                          
171 Bertrand, T. et al.; J. Mol. Biol., 396, 2010, 663-673. Structural Basis for Human Monoglyceride Lipase Inhibition. 
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 3.1 Synthesis of new molecules 
We decided to synthesise a small pool of potential MAGL inhibitors, basing on the structure of known 
URB602169. 
As shown in fig. 25, in these new molecules we inserted different small modifications, such as the 
introduction of -F or -CF3 residues on the biphenyl side (compounds 2a and 3a), different carbocyclic 
or aromatic rings bound through short spacers (1a, 1b, 1c or 1d), or both the things together (2b, 2c, 
3b). 
 
Fig. 25: Library of URB602 synthetic analogues 
We also synthesised a molecule containing an ureic structure -compound 1e - instead of the classical 
carbamate scaffold, to verify what happens with the substitution of the H-bond acceptor oxygen of 
the carbamate with the mostly H-donor nitrogen atom. 
The synthesis was made using the general procedure described by Szabo et al169, which consisted in 
a two steps process (scheme 11).  
The first one was a Suzuki palladium tetrakis-catalysed reaction: the appropriate phenilboronic acid 
was reacted at reflux with m-bromoaniline in the presence of sodium carbonate, in dry CH3OH, to 
give an intermediate biphenylamine (42 - 65% yield, 4a-c).  
The second step was the activation, at reflux, of the intermediate with carbonyl diimidazole (CDI), 
using DMAP as catalyst and in dry acetonitrile; the subsequent addition in the medium of the proper 
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alcohol and the heating for the necessary time of reaction gave the different desired products with 
medium to good yields (tab. 4). 
 
Scheme 11: Synthetic route for URB602 analogues 
 
Molecule R- R’- 
Reaction iii) 
time  
Yield 
URB602 H 
 
24 h 69% 
1a H 
 
48 h 30% 
1b H 
 
24 h 72% 
1c H 
 
24 h 54% 
1d H 
 
24 h 45% 
2a CF3 
 
24 h 58% 
2b CF3 
 
24 h 64% 
2c CF3 
 
12 h 70% 
3a F 
 
24 h 74% 
3b F 
 
24 h 80% 
Tab. 4: Reaction yields and conditions 
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For ureic molecule 1e, the first step was the same previously described; otherwise, after the activation 
of intermediate biphenylamine with CDI, the following addition of phenol resulted in the sudden 
precipitation of a white solid, which resulted to be the symmetric ureic molecule 1e and not the desired 
product bearing a phenolic residue directly linked on the carbamate oxygen as expected. 
In this way we obtained a small stock of analogues of reference URB602, ready to be tested on their 
activity on hMAGL. 
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4. ACTIVITY EVALUATION OF NEW SYNTHETIC MOLECULES 
After an initial study using the p-nitrophenyl alkyl esters method, synthetic molecules were studied 
on their potential to inhibit hMAGL using the fluorescence method developed in the laboratory172, 
both on hMAGl and cellular lysates. 
 
4.1 On human recombinant MAGL (hMAGL) 
Assays were performed as described for the validation of the method, using 25ng/well of hMAGL, 5 
μM 7-HRA as substrate, 10 % DMSO as solubilizer and Tris-HCl (50mM, pH 7.4, 1 mM EDTA) as 
reaction buffer. 
All molecules were used in final concentrations that ranged from 10-9 M to 75 μM in order to calculate 
the inhibition curve against hMAGL. 
The enzyme was dissolved in Tris-HCl and added to 80 μl of buffer solution in a 96-wells black plate; 
5 μl of inhibitor solutions at different concentrations in DMSO were added and then incubated at 
room temperature for 60 min.  
The reaction was started after the incubation period by the rapid addition of 5 μl of 7-HRA 
intermediate solution to obtain the final concentration of 5 μM, in the final volume of 100 μl. The 
fluorescent signal was measured at different time points (every 3 minutes) for a period of 1 hour and 
the fluorescence unit converted to amount of resorufin basing on the calibration curve. 
The IC50 values were calculated after 30 minutes and derived from two independent experiments 
performed in triplicate, calculated as nonlinear regressions using sigmoid dose–response setting with 
variable Hill slope by GraphPad Prism 5.0 for Windows. 
 
 
 
Fig. 26: Inhibition by URB602 
Molecule URB602 was used as control to 
verify the reliability of the experiment during 
the different repeats and, as already shown, it 
gave an IC50= 9.1 ± 2.3 μM 
 
 
                                                          
172 Lauria, S. et al.; Anal Bioanal Chem, 407, 2015, 8163-8167. Synthesis and characterization of a new fluorogenic substrate for monoacylglycerol 
lipase and application to inhibition studies. 
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Molecule 1b could not be tested due to poor solubility, however molecule 1e, belonging to the family 
of ureas, was tested but showed no activity at all as inhibitor; on the contrary, it seemed to have a 
positive effect on hMAGL, increasing the hydrolytic activity on the substrate, and acting as an 
activator of the enzyme. 
 
 
Fig. 27: Inhibition by 1a 
Molecule 1a had an inhibition value slightly 
lower than URB602, with IC50= 11.1 ± 2.3 
μM. 
 
 
 
 
 
 
 
Fig. 28: Inhibition by 1c  
1c showed an IC50= 11.3 ± 1.4 μM, once 
again comparable with that of URB602. 
 
 
 
 
 
Fig. 29: Inhibition by 1d 
Molecule 1d gave an inhibition profile very 
different from its analogues, with poor 
reliability and a too much wide range of IC50 
values even with many repetitions of the 
experiment.  
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Fig. 30: Inhibition by 2a 
The same happened for molecule 2a 
showing IC50= 10.5 ± 2 μM, with no 
increasing of the activity. 
 
 
 
 
 
 
 
Fig. 31: Inhibition by 2b 
The best value was obtained with molecule 
2b: IC50= 4.5 ± 0.7 μM, seeming to have an 
inhibitory activity double than URB602. 
 
 
 
 
 
 
Fig. 32: Inhibition by 2c 
The furanic-fluorinated inhibitor 2c had a 
slight increase of activity compared to the 
reference, having IC50= 6.7 ± 0.7 μM. 
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Fig. 33: Inhibition by 3a 
Molecule 3a had IC50= 13.4 ± 0.9 μM, once 
again comparable with reference molecule. 
 
 
 
 
 
 
 
 
 
 
Fig. 34: Inhibition by 3b 
The analogue 3b showed a small increase of 
URB602 activity, with IC50= 7.9 ± 0.8 μM. 
 
 
 
As possible to verify from the graphs, the general behaviour of all molecules is very similar to that of 
reference URB602. 
Molecules 1a, 1c, 2a and 3a showed an IC50 value comparable to that of URB602, around 10 μM; 
molecule 1e (not reported) demonstrated to be an activator of the enzyme, causing a huge increase of 
the fluorescent signal. 
Better inhibition values were obtained with molecule 3b, 2c, and - in particular - with 2b, which 
showed IC50= 7.9 ± 0.8 μM, IC50= 6.7 ± 0.7 μM and IC50= 4.5 ± 0.7 μM respectively. 
From these data, the suggestion could be that the contemporary insertion of a fluorinated residue 
(present in each of these molecules) on the biphenyl side and of an aromatic substituent (benzene ring 
for 2b/3b and furanic ring for 2c) bound through a one-carbon linker on the oxygen side of the 
structure, seem to be important for the interactions with the enzyme. 
These interactions are favourably translated in the inhibition of MAGL (tab. 5), with a decrease of 
its activity in the assay, which is the aim of the study. 
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Compound IC50 (µM) 
URB602 9.1 ± 2.3 
1a 11.1 ± 2.3 
1c 11.3 ± 1.4 
2a 10.5 ± 2 
2b 4.5 ± 0.7 
3a 13.4 ± 0.9  
3b 7.9 ± 0.8  
2c 6.7 ± 0.7  
Tab. 5: Inhibition values of different compounds 
 
4.2 On cancer cell lysates 
The same experiment was performed in vitro using cancer cell lysates, in order to verify the feasibility 
of the new fluorescent method and to prove the eventual activity of inhibitory molecules on tissue 
samples. 
The hydrolytic activity of MAGL on cell lysates was conducted using the fluorogenic substrate 
previously described.  
Briefly, cells (B16-F10 melanoma cells, Lewis lung carcinoma cells, Gl261 glioma cells)173,174 were 
cultured in Dulbecco’s modified medium supplemented with 10% heat-inactivated foetal bovine 
serum (FBS), glutamine (200 mM), penicillin/streptavidin (100 U/ml), 1% Hepes 1M pH 7.4 and 
grown at 37°C in a humidified atmosphere containing 5% CO2.  
After 36 h of culture, cells were homogenised for 30 min at 4° C in lysis buffer (10 mM Tris, 150 
mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100 with protease inhibitor mixture, pH 7.4) and 
lysates were then centrifuged for 5 min at 1,500 × g.  
The assay was carried out in a 96-well format using 1 g of cell lysate and 10 M of substrate. 
Fluorescence was measured at 588 nm (λex.571 nm/λem.588 nm) by a Glomax-Microplate Multimode 
Reader (Promega) every 2 min for 2 h.  
To test the inhibitors, B16-F10 melanoma cells lysate was pre-treated for 60 min with DMSO or the 
inhibitors at different concentrations.  
Then, the substrate was added to each well and fluorescence was measured every 2 min for 2 h.  
The graphs show the results after 5 min of incubation. Values are expressed as mean ± SEM (n = 3). 
                                                          
173Hamtiaux, L. et al.; BMC Cancer., 12, 2012; 92-97. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma 
growth through a supra-additive action. 
174 Aaltonen, N. et al.; Chem. Biol., 20, 2013, 379-390. Piperazine and Piperidine Triazole Ureas as Ultrapotent and Highly Selective Inhibitors of 
Monoacylglycerol Lipase. 
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Each molecule was tested in a range of concentration from 0 to 75 μM, in relative high concentrations, 
as suggested from previous studies on URB602175, in which it showed to have a modest activity in 
terms of potency when used on cells or cell lysates. 
Ureic molecule 1e (not reported) showed no activity at all as inhibitor but as already mentioned, 
seemed to increase the activity of the enzymatic apparatus. 
Analogue 1b was not tested due to solubility problems and molecule 1d for the reported 
unrepeatability of results showed with hMAGL. 
All other molecules were tested: in each graph below, relative to B16-F10 melanoma cells lysate, red 
lines with circles are control molecule URB602, otherwise black lines with squares are relative to test 
compounds. 
 
 
    1a       1c 
 
    2a       2b 
Fig. 35 (continues) 
                                                          
175 King, A. et al.; Chem. Biol., 14, 2007, 1357-1365. URB602 Inhibits Monoacylglycerol Lipase and Selectively Blocks 2-Arachidonoylglycerol 
Degradation in Intact Brain Slices. 
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    2c       3a 
 
3b 
Fig. 35: Use of synthetic compounds on B16-F10 melanoma cells lysate 
As possible to see from fig. 35, the general trend among all molecules is very similar to that of 
URB602: in terms of potency, all molecules have the same behaviour of the reference one, with 
activities that are appreciable with relatively high amount of inhibitor (in the field of μM 
concentrations). Only molecules 3b and 2c have an activity increase that is significantly different 
from URB602 - but however, in the field of μM concentration - too high for a direct development as 
possible drugs. 
The essentially overlapping results between URB602 and most of the tested molecules are due to the 
low differences in terms of activity obtained with the fluorogenic method using hMAGL.  
The small differences that spread out on the pure enzyme were not highlighted with the use of cell 
lysates because of the presence of all other lipases that are present in cells, and that – obviously - can 
produce interferences that have to be evaluated. 
Anyway, the general results seemed to confirm the potential of these molecules as starting point for 
the development of more potent MAGL inhibitors, with perspectives in cancer-treatment 
applications.  
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5. MOLECULAR MODELLING STUDY 
The in silico screening was carried out by Dr. Eberini’s group, using the Dock program contained in 
the MOE Simulation module176.  
The full MAGL structure obtained from the Protein Data Bank (PDB code 3JW8171) was set as 
receptor.  
Before starting with the placement procedure, 1.000 conformations were generated for each ligand 
by sampling their rotable bonds.  
The selected placement methodology was Triangle Matcher, in which the poses are generated by 
superposing triplets of ligand atoms and triplets of receptor site points; the receptor site points are 
alpha spheres centres that represent locations of tight packing. 
Before scoring all the generated poses, duplicate complexes were removed; poses are considered as 
duplicates if the same set of ligand-receptor atom pairs are involved in hydrogen bond interactions 
and the same set of ligand atom receptor residue pairs are involved in hydrophobic interactions.  
The accepted poses were scored according to the London dG scoring, which estimates the free energy 
of binding of the ligand from a given pose.  
Δ𝐺 = 𝑐 + ∑ 𝑐𝐻𝐵𝑓𝐻𝐵
ℎ−𝑏𝑜𝑛𝑑𝑠
+ ∑ 𝑐𝑀𝑓𝑀
𝑚−𝑙𝑖𝑔
 +  ∑ ∆𝐷𝑖
𝑎𝑡𝑜𝑚𝑠_𝑖
 
where c represents the average gain/loss of rotational and translational entropy; Eflex is the energy due 
to the loss of flexibility of the ligand (calculated from ligand topology only); fHB measures geometric 
imperfections of hydrogen bonds and takes a value in [0,1]; cHB is the energy of an ideal hydrogen 
bond; fM measures geometric imperfections of metal ligations and takes a value in [0,1]; cM is the 
energy of an ideal metal ligation; and Di is the desolvation energy of atom i. The difference in 
desolvation energies is calculated according to the formula 
∆𝐷𝑖 = 𝑐𝑖𝑅𝑖
3 {∭ |𝑢|−6𝑑𝑢 − ∭ |𝑢|−6𝑑𝑢
𝑢∉𝐵𝑢∉𝐴∪𝐵
} 
where A and B are the protein and/or ligand volumes with atom i belonging to volume B; Ri is the 
solvation radius of atom i (taken as the OPLS-AA van der Waals sigma parameter plus 0.5 A° ); and 
ci is the desolvation coefficient of atom i. The coefficients {c, cHB, cM, ci} have been fitted from 
approx. 400 x-ray crystal structures of protein–ligand complexes with available experimental pKi 
data. Atoms are categorized into about a dozen atom types for the assignment of the ci coefficients. 
The triple integrals are approximated using Generalized Born integral formulas. Only the top scoring 
                                                          
176 Eberini, I. et al.; Cellular Signalling, 26, 2014, 2614-2620. Oxysterols act as promiscuous ligands of class-A GPCRs: In silico molecular modeling and 
in vitro validation. 
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solution was kept and submitted to a further refinement step, based on molecular mechanics (MM). 
In order to speed up the calculation, residues over a 6 A° cut-off distance away from the pre-refined 
pose were ignored, both during the refinement and in the final energy evaluation. All receptor atoms 
were held fixed during the refinement.  
During the course of the refinement, solvation effects were calculated using the reaction field 
functional form for the electrostatic energy term.  
The final energy was evaluated using the MMFF94x force field with the Generalized Born solvation 
model (GBIV) The estimated 
binding affinity and the ligand 
efficiency were calculated 
through the MOE LigX module. 
The pKi was computed through 
the binding free energy estimated 
with the London dG scoring 
function.  
 
Fig. 36: MAGL’s upper active 
site 
 
In fig. 36 is shown the so called 
“upper active site” of MAGL, a 
region which is in the near 
proximity of the catalytic active site and that has already been described by Szabo et al169 as one of 
the top scoring area for the interaction with potential inhibitors. 
This area is characterised by the presence of Cys residues which have been identified as important171 
for the activity of MAGL; in fact, the use of mercuric compounds (p-chloromercuribenzoic acid or 
mercury chloride) leads to the inactivation of the enzyme as shown by Tornqvist and Belfrage177. 
                                                                        
                                                          
177 Tornqvist, H. et al.; J. Biol. Chem. 251 (3), 1976, 813-819. Purification and Some Properties of a Monoacylglycerolhydrolyzing Enzyme of Rat Adipose 
Tissue. 
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Fig. 37: Library compounds docked in the binding site 
After the identification of the binding site, all molecules were docked in this area (fig.37) showing a 
good overlap with each other for what concerns the basic biphenyl-carbamate portion.  
From this calculation, the parameters relative to binding scores and affinities were obtained (tab. 6). 
 
Compound S rmsd_refine E_conf E_place E_score1 E_refine E_score2 Affinity 
2b -5.9430838 0.58281505 78.291893 -66.040695 -10.551647 9.3805799 -5.9430838 -7.51 
2c -5.0423589 0.7060526 61.225021 -70.984642 -11.266261 -11.543186 -5.0423589 -7.45 
3b -4.8428435 0.41026047 71.469421 -74.062782 -9.978035 9.6461573 -4.8428435 -7.23 
2a -4.7799511 0.44828889 59.427479 -92.349586 -10.491234 -5.8264842 -4.7799511 -6.53 
1d -4.7777739 0.67168045 61.030651 -78.702347 -9.6511679 -2.436954 -4.7777739 -6.67 
1e -4.6375728 0.63646847 106.74659 -84.480141 -10.593376 28.71034 -4.6375728 -7.95 
3a -4.2893596 0.63039917 56.280289 -75.822365 -10.364834 -8.0055685 -4.2893596 -6.95 
1c -4.25176 0.77640748 117.52163 -92.035095 -9.7479868 51.337315 -4.25176 -6.65 
1b -4.1275358 0.70628202 74.800369 -82.03463 -9.8570385 7.1317501 -4.1275358 -7.10 
1a -4.1032023 0.83517736 73.456062 -62.114296 -10.158004 12.805244 -4.1032023 -6.97 
URB602 -3.7279174 0.67099124 56.486671 -64.88781 -9.6643295 -7.2782025 -3.7279174 -6.86 
Tab. 6: Docking scores 
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From the table is possible to verify that the best “docking score” (or “binding free energy”, value S) 
was relative to synthetic inhibitor 2b (-5.9430838) - which also showed the best inhibitory activity 
using the fluorescent method previously described. 
Concerning affinities, the best value was obtained for molecule 1e (-7.95) which had no inhibitory 
effect on the enzyme, but on the contrary seemed to be an activator; its activating effect on MAGL is 
compatible with its affinity value, but needs to be studied in more details. 
 
In terms of pKi values, due to the 
limit of this method (accuracy 
about one order of magnitude) 
there is no possibility of 
discrimination among the 
different structures, which have 
all (except 1e of course) pKi=5, 
that is compatible with the 
experimental IC50 values, in the 
range of micro molar 
concentrations. 
 
 
 
 
 
 
 
 
 
 
    Fig. 38: Molecule 2b docked to MAGL 
As mentioned above, best fit values were shown by 2b: from fig.38 and fig. 39 is possible to see the 
interactions with the upper active site of MAGL: the molecule accommodates in a pocket that is rich 
in hydrophobic residues, such Leu and Ile; in particular, hydrophobic interactions occur between the 
side chain of Ile-189 and the benzene ring present at the oxygen side of the carbamate molecule. 
A ligand exposure at the level of the carbonyl oxygen takes place in proximity of Tyr-204, suggesting 
the possible formation of H-bond interactions. 
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Another ligand exposure takes 
place at the trifluoromethyl 
residue, linked to the biphenyl 
portion of the molecule, which is 
stretched in the direction of Asn-
162 and Leu-215. 
Overall, these indications - 
docking scores and affinity values 
in particular - can suggest that the 
contemporary introduction of 
small polar atoms on one side and 
of an aromatic ring on the other 
produces an increase of the 
interactions occurring between 
the potential inhibitor and the 
enzyme. 
  Fig. 39: 2b disposition 
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6. CONCLUSION AND FUTURE DIRECTIONS 
The endocannabinoid system (ECS) is a multifaceted entity with enormous therapeutic potential. 
In the field of ECS understanding - and of MAGL in particular - a lot has to be done yet the work 
outlined in this thesis contributes to the advancement in MAGL knowledge. 
One of the major problems in the study of possible active molecules, as MAGL inhibitors, is the 
availability of easy and reliable screening assays, both in vitro and in vivo. 
Many methods are known, but all of them show different characteristics in terms of selectivity, 
sensitivity, costs of analysis and availability of the analytical equipment. 
With the development of the new fluorogenic screening assay based on the use of 7-HRA, we tried 
to help to overcome the problems related to the sensitivity of the method and its feasibility in cellular 
screening assays. 
In the first part of this research project, we have synthesized a red flurogenic substrate, 7-
hydroxyresorufinyl-arachidonate (7-HRA), for a new assay for mammalian MAGL inhibition studies. 
This assay is based on the enzymatic hydrolysis of a readily synthesized 7-HRA that results in the 
production of a fluorescent resorufin, with reduction of interferences due to the auto-fluorescence of 
cell membranes in the field of blue emitting wavelengths, giving a method useful even for in vitro 
tests on living cells. 
The fluorometric method, validated using three known MAGL inhibitors, proved to be rapid, 
versatile, and compatible with high-throughput screening.  
The assay will be applied for the development of new MAGL inhibitors as therapeutic agents that 
modulate the endocannabinoid system activity.  
Moreover, the fluorometric assay could be a useful tool for further investigations into the relationship 
between MAGL inhibition and regulation of analgesia, inflammation, anxiety, and other disorders. 
In the second part of this study, we have explored structural modifications of URB602 with the aim 
of producing inhibitors that could be more potent.  
Starting from URB602 scaffold we designed and synthesized ten different new compounds carrying 
modifications on the three main parts of the molecule (biphenyl side, carbamate group and substituent 
at the oxygen side), to evaluate how these modifications (insertion of H-bond promoting groups, as -
F or –NH, and/or hydrophobic interactions promoting residues) influence the inhibitory activity 
toward MAGL. 
The synthesis of novel MAGL inhibitors was achieved with simple synthetic routes and in satisfactory 
yields; the molecules were tested with the new fluorogenic method on their ability to inhibit human 
recombinant MAGL and encouraging results were obtained. 
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All molecules showed a satisfactory inhibitory activity (comparable to that of reference molecule 
URB602) and better inhibition values were obtained with molecule 2b, 2c, and 3b, which showed 
IC50= 4.5 ± 0.7 μM, IC50= 6.7 ± 0.7 μM and IC50= 7.9 ± 0.8 μM, respectively. 
The following modelling study helped to understand the possible role of the inserted substituents in 
MAGL inhibition; the contemporary insertions of –F residues on the biphenyl side and of an aromatic 
substituent through a one-carbon linker on the oxygen side, seem to be important for a good 
interaction with the enzyme. 
A further step would be to verify if these new active compounds maintain their inhibitory effect in 
vivo. 
Considering this work in particular, a deep study on whole cells has to be done, to evaluate the 
possibility to use the fluorogenic method on the constitutive MAGL enzyme in living cells. 
Cancer cells could be a good model for these studies due to the naturally high expression of MAGL 
in cancer; consequently, we decided to optimize the conditions of the fluorogenic method on B16-
F10 melanoma cell lysates. 
The results obtained on cancer cell lysates seem to indicate that the potencies of the new synthetic 
molecules are too close one to the other to have a discrimination of their effect in vivo, but in any 
case a study on their effects on cancer cell lines is still necessary to evaluate if there a positive 
response to their administration. 
We are still far from the definitive discover of potent, selective and safe MAGL inhibitors, but all 
these studies can help to trace the way to reach that goal. 
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7. MATERIALS AND INSTRUMENTS 
7.1 Reagents 
Monoacylglycerol lipase (human recombinant, 25 μg) was purchased from Cayman Chemical (Ann 
Arbor, MI, USA); arachidonic acid, resorufin, Tris, ethylendiaminetetraacetic acid (EDTA), Hepes, 
phosphate buffered saline (PBS) tablets, and all other reagents and solvents were purchased from 
Sigma-Aldrich (St. Louis, MO, USA).  
Reaction progress was monitored by analytical thin-layer chromatography (TLC) on pre-coated 
aluminium foils (Silica Gel 60F254-plate, Sigma-Aldrich), and the products were visualized by UV 
light. 
 7.2 Instruments 
Fluorescence signals were recorded by a Promega-GloMax multidetection system using a green 
fluorescence optical kit (excitation 525 nm, emission 580–640 nm) with flat bottom 96-well black 
plate. 
IC50 values were calculated as nonlinear regressions using sigmoid dose–response setting with 
variable Hill slope by GraphPad Prism 5.0 for Windows. 
 
NMR spectra were recorded on a Bruker AVANCE 500 spectrometer equipped with a 5mm 
broadband reverse probe with field z-gradient operating at 500.13 and 125.76 MHz for 1H and 13C, 
respectively.  
NMR spectra were recorded at 298 K in CDCl3 (isotopic enrichment 99.95%), d6-DMSO (isotopic 
enrichment 99.98%) or CD3OD (isotopic enrichment 99.96%) solutions.  
The data were collected and processed by XWIN-NMR software (Bruker) running on a PC with 
Microsoft Windows 7.  
The samples (10 mg), were dissolved in the appropriate solvent (0.7 mL) in a 5 mm NMR tube. 
Acquisition parameters for 1D were as follows: 1H spectral width of 5000 Hz and 32K data points 
providing a digital resolution of ca. 0.305 Hz per point, relaxation delay 2 s; 13C spectral width of 
29,412 Hz and 64 K data points providing a digital resolution of ca. 0.898 Hz per point, relaxation 
delay 2 s (unless otherwise indicated).  
The experimental error in the measured 1H-1H coupling constants was ±0.5 Hz.  
Chemical shifts (δ) of the 1H NMR and 13C NMR spectra are reported in ppm using the signal for 
residual solvent protons resonance as internal standard (1H NMR: CDCl3 7.26 ppm , d6-DMSO 2.49 
ppm, CD3OD 4.78 ppm, (higher field signal, central line); 13C NMR: CDCl3 77.0 ppm (central line), 
d6-DMSO 39.50 ppm (central line), CD3OD 49.3 (higher field signal, central line).  
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The splitting pattern abbreviations are as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet, and bs, broad signal.  
For two-dimensional experiments, Bruker microprograms using gradient selection (gs) were applied. 
All two-dimensional spectra (COSY, HSQC and HMBC) were acquired with 2048 data points for t2 
and 256 for t1 increments.  
The long-range coupling time for HMBC was 0.07 ms. 
The confirmations of the structures were obtained by 500 MHz-NMR spectra, in particular through 
proton and carbon 1D NMR spectra, as well as by 2D NMR homo-correlation (COSY) and hetero-
correlation (HSQC and HMBC) experiments. 
Melting points were determined with a Stuart Scientific SMP3 melting point apparatus and left 
uncorrected. 
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8. CHEMICAL DATA 
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General synthetic method for new carbamate compounds 
The synthesis was made using the general procedure described by Szabo et al169, which consisted in 
a two steps process (scheme 11).  
The first one was a Suzuki palladium tetrakis-catalysed reaction: the appropriate phenilboronic acid 
was reacted at reflux with m-bromoaniline in the presence of sodium carbonate, in dry CH3OH, to 
give an intermediate biphenylamine (42 - 65% yield).  
The second step was the activation, at reflux, of the intermediate with carbonyl diimidazole (CDI), 
using DMAP as catalyst and in dry acetonitrile; the subsequent addition in the medium of the proper 
alcohol and the heating for the necessary time of reaction gave the different desired products with 
medium to good yields. 
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Synthesis of 7-hydroxyresorufinyl-arachidonate (7-HRA) 
 
To a solution of arachidonic acid (80 mg, 0.26 mmol) in dry CH2Cl2 (10 ml), oxalyl chloride (45 μl, 
0.53 mmol) in dry CH2Cl2 (1 ml) was added dropwise at 0 °C under stirring.  
N,N-dimethylformamide (DMF, 1 drop) was added next. The reaction mixture was stirred at room 
temperature for 3 h and then concentrated under vacuum, giving crude arachidonoyl chloride.  
This residue was dissolved in dry CH2Cl2 (5 ml) and added dropwise to an ice-cold suspension of 
resorufin (67 mg, 0.32 mmol) and triethylamine (55 μl, 0.39 mmol) in dry CH2Cl2 (15 ml) and then 
stirred overnight at room temperature. After dilution with CH2Cl2 the salts residues were removed by 
filtration obtaining a brick-red solution; that was washed with 1M HCl (20 ml), saturated NaHCO3 
(25 ml), dried on anhydrous sodium sulfate and concentrated to give the crude product. Column 
chromatography on silica gel (CH2Cl2:CH3OH, 95:5) gave the product (80 mg, 0.16 mmol, 62%) as 
a red oil.  
 
MM=499.6 g/mol 
 
TLC (Rf=0.84, CH2Cl2:CH3OH, 90:10).  
 
1H NMR (CDCl3, 500 MHz): δ (ppm) 7.82 (1H, d, J=8.7 Hz, 1-H), 7.46 (1H, d, J=9.8 Hz, 9-H), 7.17 
(1H, d, J=2.4 Hz, 4-H), 7.14 (1H, dd, J=8.7, 2.4 Hz, 2-H), 6.89 (1H, dd, J=9.8, 2.0 Hz, 8-H), 6.36 
(1H, d, J=2.0 Hz, 6-H), 5.52-5.33 (8H, m, 5′- 6′- 8′- 9′- 11′- 12′- 14′- and 15′-CH), 2.88-2.82 (6H, m, 
7′- 10′- and 13′-CH2), 2.65 (2H, t, J=7.0 Hz, 2′-CH2), 2.25 (2H, dt, J=7.4, 7.0 Hz, 4′-CH2), 2.07 (2H, 
dt, J=7.6, 7.6 Hz, 16′-CH2), 1.88 (2H, tt, J=7.6, 7.0 Hz, 3′-CH2), 1.39-1.28 (6H, m, 17′-19′ CH2), 0.91 
(3H, t, J=7.6 Hz, 20′-CH3).  
 
13C NMR: δ (ppm) 186.3 (3), 171.2 (1′), 153.6 (7), 149.4 (11), 148.3 (12), 144.4 (13), 135.2 (8), 134.8 
(9), 131.3 (14), 131.2 (1), 130.6 (5′, 6′, 8′, 9′, 11′, 12′, 14′, 15′),129.5, 128.7, 128.5, 128.4, 128.1, 
127.8, 127.5, 119.3 (2), 109.7 (4), 107.3 (6),  33.7 (2′), 27.2 (16′), 26.5 (4′), 25.7 (7′, 10′, 13′), 24.6 
(3′), 31.5 (18′), 29.3 (17’), 22.6 (19′), 14.1 (20′). 
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Synthesis of intermediate [1,1'-biphenyl]-3-amine (4a) 
 
To a solution of phenylboronic acid (500 mg, 4.13 mmol) in CH3OH (8 ml), Na2CO3 (911 mg, 8.6 
mmol, 2 eq.) and 3-bromoaniline (414 μl, 4.13 mmol, 1 eq.) were added. After addition of Pd(PPh3)4 
(160 mg, 0.139 mmol, 0.034 eq.) the reaction mixture was heated at reflux for 12 h. 
The solution was cooled to r.t, diluted with methanol and filtered through celite to remove the black 
precipitate;  water was added and the aqueous phase was washed with 2x15 ml CH2Cl2. 
The organic fractions were combined and dried over anhydrous Na2SO4, filtered and evaporated to 
give the crude product. 
The oily crude product was purified by chromatography on silica gel (petroleum ether:CH3OH, 90:10 
followed by 80:20) to give the final product 4a (423 mg, 2.50 mmol, 65%) as a yellow oil. 
 
MM=169.2 g/mol 
 
TLC (Rf=0.30, petroleum ether:CH3OH, 90:10). 
 
1H NMR (CDCl3, 500MHz): δ 7.58 (2H, d, J=7.4 Hz, 2΄- and 6΄-H), 7.43 (2H, dd, J=8.3, 7.4 Hz, 3΄- 
and 5΄-H), 7.35 (1H, t, J=7.4 Hz, 4΄-H), 7.24 (1H, dd, J=7.8, 7.6 Hz, 5-H), 7.01 (1H, ddd, J=7.6, 1.0, 
<1.0 Hz, 6-H), 6.92 (1H, dd, J=2.4, <1.0 Hz, 2-H), 6.69 (1H, ddd, J= 7.8, 2.4, 1.0 Hz, 4-H), 3.75 (2H, 
s, 7-NH2).  
 
13C NMR: δ 146.7 (3), 142.5 (1), 141.4 (1΄), 129.7 (5), 128.6 (3΄ and 5΄), 127.2 (4΄), 127.1 (6΄ and 
2΄), 117.7 (6), 114.1 (4), 114.0 (2). 
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Synthesis of cyclohexyl [1,1'-biphenyl]-3-ylcarbamate (URB602) 
 
CDI (959 mg, 5.92 mmol, 4 eq.), DMAP (36.2 mg, 0.296 mmol, 0.2 eq.) and byphenyl-3-ylamine 4a 
(251 mg, 1.48 mmol, 1 eq.) were mixed in dry AcCN (5 ml) and heated at reflux overnight; 
cyclohexanol (2.35 ml,  22.2 mmol, 15 eq.) was added to the obtained red solution and the reaction 
heated at 100°C for 24 h.   
The reaction was cooled to r.t and evaporated in vacuo to give the crude product, which was then 
purified by chromatography on silica gel using a mixture petroleum ether:EtOAc, 95:5; the final 
product was then recovered by crystallisation adding cold n-hexane to its solution in CH2Cl2, 
obtaining 302 mg (1.02 mmol, 69%) of URB602 as white needles. 
 
MM=295.4 g/mol 
 
TLC (Rf=0.22, petroleum ether:ethyl acetate, 95:5).  
 
mp: 119.6-121.3 °C 
 
1H NMR (CDCl3, 500MHz): (ppm) 7.70 (1H, s, 2-H), 7.62 (2H, d, J=7.2 Hz, 2’- and 6’-H), 7.45 
(2H, t, J=7.6 Hz, 3’- and 5’-H), 7.42-7.34 (3H, m, 4’- 5- and 6-H), 7.32 (1H, d, J=7.1 Hz, 4-H), 6.67 
(1H, s, 7-NH), 4.81 (1H, m, 9-CH), 2.03-1.92 (2H, m, 10-Heq and 14-Heq), 1.84-1.74 (2H, m, 11-Heq 
and 13-Heq), 1.62-1.56 (1H, m, 12-Heq), 1.56-1.47 (2H, m, 10-Hass and 14-Hass), 1.47-1.38 (2H, m, 
11- Hass and 13’-Hass), 1.30 (1H, m, 12-Hass). 
 
13C NMR: δ (ppm) 153.2 (8), 142.2 (3), 140.8 (1), 138.5 (1’), 128.8 (5), 127.2 (2’, 4’ and 6’), 127.5 
(3’ and 5’), 122.1 (4), 117.4 (2 and 6), 73.8 (9), 32.0 (10 and 14), 25.4 (12), 23.9 (11 and 13). 
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Synthesis of benzyl [1,1'-biphenyl]-3-ylcarbamate (1a) 
 
CDI (1148 mg, 7.08 mmol, 4 eq.), DMAP (43.3 mg, 0.354 mmol, 0.2 eq.) and byphenyl-3-ylamine 
4a (300 mg, 1.77 mmol, 1 eq.) were mixed in dry AcCN (8 ml) and heated at reflux overnight; phenyl 
methanol (917 μl, 8.85 mmol, 5 eq.) was added and the reaction heated at 100°C for 48 h obtaining a 
clear brown mixture. 
The solution was cooled to r.t, the solvent removed by evaporation and the crude product purified by 
chromatography on silica gel (petroleum ether:EtOAc, 90:10); the crystallisation in CH2Cl2/cold n-
hexane gave product 1a (148 mg, 0.49 mmol, 30%) as a white powder. 
 
MM=303.4 g/mol 
 
TLC (Rf=0.33, petroleum ether:ethyl acetate, 95:5).  
 
mp: 73.2-73.9 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.68 (1H, br. s, 2-H), 7.61 (2H, d, J=7.3 Hz, 2’- and 6’-H), 
7.48-7.43 (5H, m, 3’- 4’- 5’- 12- and 14-H), 7.42 (1H, s, 4-H), 7.41-7.36 (4H, m, 11- 13- 15- and 6-
H), 7.33 (1H, dd, J=8.7, 1.8 Hz, 5-H), 6.79 (1H, br. s, 7-NH), 5.26 (2H, s, 9-CH2). 
 
13C NMR: δ (ppm) 153.4 (8), 142.3 (3), 140.7 (1), 138.2 (1’), 136.1 (10), 129.5 (5), 128.8 (3’ and 5’), 
128.7 (12 and 14), 128.4 (6, 2’ and 6’), 128.4 (4), 127.5 (4’ and 13), 127.2 (11 and 15), 122.4 (2), 
67.1 (9). 
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Synthesis of 1-phenylethyl [1,1'-biphenyl]-3-ylcarbamate (1b) 
 
 
CDI (574.7 mg, 3.54 mmol, 4 eq.), DMAP (21.7 mg, 0.18 mmol, 0.2 eq.) and byphenyl-3-ylamine 
4a (150 mg, 0.88 mmol, 1 eq.) were mixed in dry AcCN (5 ml) and heated at reflux overnight; 1-
phenylethanol (531 μl, 4.43 mmol, 5 eq.) was added and the reaction heated at 100°C for 24 h till the 
obtaining of a turbid pink solution. 
After cooling to r.t, the solvent was removed by evaporation and the crude product purified by 
chromatography on silica gel (petroleum ether:EtOAc, 90:10), giving product 1b (203 mg, 0.64 
mmol, 72%) as a yellow oil. 
 
MM=317.4 g/mol 
 
TLC (Rf=0.28, petroleum ether:ethyl acetate, 90:10).  
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.68 (1H, s, 2-H), 7.59 (2H, d, J=7.8 Hz, 2’- and 6’-H), 7.48-
7.42 (4H, m, 3’- 4’- 5’- and 4-H), 7.41-7.19 (7H, m, 5- 6- 12- 13- 14- 15- and 16-H), 6.75 (1H, s, 7-
NH), 5.95 (1H, q, J=6.6 Hz, 9-CH), 1.65 (3H, d, J=6.6 Hz, 10-CH3). 
 
13C NMR: δ (ppm) 153.8 (8), 144.5 (11), 143.9 (3), 143.1 (5), 131.7 (1 and 1’), 130.9 (3’ and 5’), 
130.3 (13 and 15), 129.8 (2’and 6’), 129.5 (4’and 14), 128.4 (12 and 16), 124.6 (6), 119.7 (2 and 4), 
75.7 (9), 24.6 (10). 
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Synthesis of phenethyl [1,1'-biphenyl]-3-ylcarbamate (1c) 
 
CDI (747 mg, 4.6 mmol, 4 eq.), DMAP (28.0 mg, 0.23 mmol, 0.2 eq.) and byphenyl-3-ylamine 4a 
(195 mg, 1.15 mmol, 1 eq.) were mixed in dry AcCN (8 ml) and heated at reflux overnight; 2-
phenylethanol (1100 μl, 9.22 mmol, 8 eq.) was added and the reaction heated at 100°C for 24 h 
obtaining an orange clear solution. 
The reaction was cooled to r.t, the solvent was removed by evaporation and the crude product purified 
by chromatography on silica gel (petroleum ether, 100 followed by petroleum ether:EtOAc, 80:20); 
the crystallisation in CH2Cl2/cold n-hexane gave product 1c (200.4 mg, 0.63 mmol, 54%) as a white 
crystalline solid. 
 
MM=317.4 g/mol 
 
TLC (Rf=0.41, petroleum ether:ethyl acetate, 80:20).  
 
mp: 98.2-99.4 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.66 (1H, br. s., 2-H), 7.61 (2H, d, J=7.6 Hz, 2’- and 6’-H), 
7.46 (2H, t, J=7.6 Hz, 3’- and 5’H), 7.42-7.37 (3H, m, 4- 4’- and 5-H), 7.37-7.31 (3H, m, 6- 13- and 
15-H), 7.29 (3H, d, J=7.4 Hz, 12- 16- and 14-H), 6.69 (1H, br. s., 7-NH), 4.45 (2H, t, J=6.9 Hz, 9-
CH2), 3.04 (2H, t, J=6.9 Hz, 10-CH2). 
 
13C NMR: δ (ppm) 153.5 (8), 141.9 (1’), 140.6 (1 and 3), 137.8 (11), 129.2 (4’), 128.82 (12  and 16), 
128.80 (3’ and 5’), 128.78 (13 and 15), 128.4 (4 and 5), 127.2 (2’ and 6’), 127.22 (14), 122.3 (6), 
117.5 (2), 65.7 (9), 35.5 (10). 
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Synthesis of furan-2-ylmethyl [1,1'-biphenyl]-3-ylcarbamate (1d) 
 
To a solution of 4a (250 mg, 1.48 mmol, 1 eq.) in dry AcCN (10 ml) were added CDI (350 mg, 2.22 
mmol, 1.5 eq.) and DMAP (90 mg, 0.74 mmol, 0.5 eq.); the mixture was heated at reflux for 24 h. 
Freshly distilled 2-furfuryl alcohol (767 μl, 8.88 mmol, 6 eq.) was added and the reaction heated at 
100°C for 24 h giving a yellow solution. 
After cooling to r.t, the solvent was evaporated and the crude product purified by chromatography on 
silica gel (petroleum ether:EtOAc, 90:10 followed by 70:30); giving the brown oil product 1d in low 
amount (195 mg, 0.66 mmol, 45%). 
 
MM=293.3 g/mol 
 
TLC (Rf=0.61, petroleum ether:ethyl acetate, 75:25).  
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.67 (1H, br. s, 2-H), 7.60 (2H, dd, J=7.8, 1.3 Hz, 2’- and 6’-
H), 7.49-7.46 (3H, m, 13- 3’- and 5’-H), 7.45 (1H, d, J=7.9 Hz, 4’-H), 7.41-7.35 (2H, m, 5- and 6-
H), 7.35-7.30 (1H, dt, J=7.0, 1.7 Hz, 4-H), 6.77 (1H, s, 7-NH), 6.50 (1H, t, J=3.8 Hz, 11-H), 6.41 
(1H, dd, J=4.1, 2.1 Hz, 12-H), 5.21 (2H, s, 9-CH2). 
 
13C NMR: δ (ppm) 153.3 (8 and 10), 143.4 (13, 3’ and 5’), 130.4 (3), 128.8 (4’), 127.5 (1 and 1’), 
127.2 (5, 2’ and 6’), 122.5 (4), 117.6 (2 and 6), 110.8 (11), 110.7 (12), 58.2 (9). 
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Synthesis of 1,3-di([1,1'-biphenyl]-3-yl)urea (1e) 
 
CDI (1148 mg, 7.08 mmol, 4 eq.), DMAP (43.3 mg, 0.354 mmol, 0.2 eq.) and byphenyl-3-ylamine 
4a (300 mg, 1.77 mmol, 1 eq.) were mixed in dry AcCN (8 ml) and heated at reflux overnight; phenol 
(777 μl, 8.85 mmol, 5 eq.) was added to the obtained red solution and the reaction heated at 100°C 
for 6 h obtaining a suspension of a white solid. 
After cooling to r.t the solid was filtered under vacuum, washed with cold CH2Cl2/AcCN to remove 
the excess of CDI, and dried to obtain 255 mg (0.70 mmol, 79%) of 1e as a white crystalline solid. 
 
MM=364.4 g/mol 
 
TLC (Rf=0.24, petroleum ether:ethyl acetate, 90:10).  
 
mp: 258.2-259.0 °C 
 
1H NMR (d6-DMSO, 500 MHz): (ppm) 8.85 (2H, s, 7-NH), 7.84 (2H, t, J=1.6 Hz, 2-H), 7.64 (4H, 
dd, J=8.2, 1.0 Hz, 2’- and 6’-H), 7.49 (4H, t, J=7.6 Hz, 3’- and 5’-H), 7.43 (2H, t, J=4.9 Hz, 4’-H), 
7.39 (4H, dt, J=7.5, 1.3 Hz, 5- and 6-H), 7.28 (2H, dt, J=7.5, 1.3 Hz, 4-H). 
 
13C NMR: δ (ppm) 153.2 (8), 141.9 (1), 140.8 (1’), 140.7 (3), 129.9 (5), 129.4 (3’ and 5’), 128.0 (6), 
127.2 (2’ and 6’), 120.9 (4), 117.9 (4’), 117.1 (2). 
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Synthesis of intermediate 4'-(trifluoromethyl)-[1,1'-biphenyl]-3-amine (4b) 
 
4-(Trifluoromethyl)phenylboronic acid (500 mg, 2.63 mmol, 1 eq.) was dissolved in CH3OH (7 ml); 
Na2CO3 (558 mg, 5.27 mmol, 2 eq.) and 3-bromoaniline (430 μl, 3.95 mmol, 1.5 eq.) were added. 
Pd(PPh3)4 (103 mg, 0.09 mmol, 0.034 eq.) was added to the mixture under argon and the reaction was 
heated at reflux for 10 h, obtaining a dark suspension. 
The mixture was cooled to r.t, diluted with methanol and filtered through celite to remove the black 
precipitate; water was added and the aqueous phase was washed with 2x15 ml CH2Cl2. 
The organic fractions were combined and dried over anhydrous Na2SO4, filtered and evaporated to 
give an oily orange crude product; that was purified by chromatography on silica gel (petroleum 
ether:CH3OH, 90:10 followed by 70:30) and crystallisation with CH2Cl2/cold n-hexane gave the final 
product 4b (258 mg, 1.05 mmol,  42%) as a white crystalline solid. 
 
MM=237.2 g/mol 
 
TLC (Rf=0.42, petroleum ether:ethyl acetate, 70:30).  
 
mp: 90.2-90.8 °C 
 
1H NMR (CD3OD, 500 MHz): (ppm) 6.24 (2H, d, J=8.2 Hz, 3’- and 5’-H), 6.19 (2H, d, J=8.2 Hz, 
2’- and 6’-H), 5.77 (1H, t, J=7.9 Hz, 5-H ), 5.61 (1H, J<1 Hz, 2-H), 5.59 (1H, d, J<1 Hz, 6-H), 5.37 
(1H, dd, J=11.7, 4.7 Hz, 4-H). 
 
13C NMR: δ (ppm) 144.3 (3), 140.8 (1’), 138.3 (1), 129.4 (5 and 4’), 127.5 (2’ and 6’), 125.7 (3’ and 
5’), 122.5 (4 and 8), 118.4 (6), 117.4 (2). 
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Synthesis of cyclohexyl (4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)carbamate (2a) 
 
To a solution of 4b (125 mg, 0.527 mmol, 1 eq.) in dry AcCN (8 ml), CDI (342 mg, 2.11 mmol, 4 
eq.) and DMAP (12.9 mg, 0.105 mmol, 0.2 eq.) were added and the mixture heated at reflux 
overnight; cyclohexanol (557 μl, 5.27 mmol, 10 eq.) was added to the obtained red solution and the 
reaction heated at 100°C for 24 h.  
The reaction was cooled to r.t, the solvent was removed by evaporation and the crude product purified 
by chromatography on silica gel (petroleum ether:EtOAc, 90:10 followed by 80:20); the 
crystallisation in CH2Cl2/cold n-hexane gave product 2a (111.3 mg, 0.31 mmol, 58%) as a fine white 
solid. 
 
MM=363.4 g/mol 
 
TLC (Rf=0.62, petroleum ether:ethyl acetate, 80:20).  
 
mp: 124.8-126.2 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.78 (1H, s, 2-H), 7.74-7.67 (4H, t, J=9.6 Hz, 2’- 3’-5’ and 6’-
H), 7.42 (1H, t, J=7.8 Hz, 5-H), 7.36 (1H, d, J=7.9 Hz,4-H), 7.31 (1H, d, J=7.5 Hz, 6-H), 6.69 (1H, s, 
7-NH), 4.84-4.74 (1H, m, 10-CH), 1.97 (2H, dd, J=8.0, 2.3 Hz, 11-Heq and 15-Heq), 1.79 (2H, dd, 
J=10.1, 4.4 Hz, 12-Heq and 14-Heq), 1.61 (1H, s, 13-Heq), 1.49 (2H, dd, J=12.4, 10.4 Hz, 11-Hass and 
15-Hass), 1.42 (2H, dd, J=12.7, 10.9 Hz, 12-Hass and 14-Hass), 1.33-1.27 (1H, m, 13-Hass). 
 
13C NMR: δ (ppm) 153.2 (9), 146.3 (1), 144.3 (1’), 140.7 (4’), 138.8(3), 129.6 (5), 127.5 (2’ and 6’), 
125.7 (3’ and 5’), 122.1 (6), 118.2 (4), 117.4 (2), 73.9 (10), 32.0 (11 and 15), 25.4 (13), 23.8 (12 and 
14). 
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Synthesis of benzyl (4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)carbamate (2b) 
 
CDI (342 mg, 2.11 mmol, 4 eq.), DMAP (12.9 mg, 0.105 mmol, 0.2 eq.) and 4b (125 mg, 0.527 
mmol, 1 eq.) were mixed in dry AcCN (8 ml) and heated at reflux overnight; phenyl methanol (546 
μl, 5.27 mmol, 10 eq.) was added and the reaction heated at 100°C for 24 h obtaining a yellow 
solution. 
The reaction was cooled to r.t, the solvent was removed by evaporation and the crude product purified 
by chromatography on silica gel (petroleum ether, 100 followed by petroleum ether:EtOAc 80:20); 
the crystallisation with CH2Cl2/cold n-hexane gave product 2b (126 mg, 0.34 mmol, 64%) as a white 
crystalline solid. 
 
MM=371.4 g/mol 
 
TLC (Rf=0.59, petroleum ether:ethyl acetate, 80:20).  
 
mp: 114.6-116.0 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.75 (1H, s, 2-H), 7.70 (4H, s, 3’- 5’- 4- and 5-H), 7.49-7.35 
(7H, m, 2’- 6’- 12- 13- 14- 15- and 16-H), 7.33 (1H, dt, J=7.4, 1.5 Hz, 6-H), 6.80 (1H, s, 7-NH), 5.27 
(2H, s, 10-CH2). 
 
13C NMR: δ (ppm) 153.3 (9), 144.3 (1), 140.8 (1’), 138.5 (3), 135.9 (11), 129.7 (4’), 128.7 (13 and 
15), 128.5 (2’ and 6’), 128.4 (12 and 16), 127.5 (14), 125.9 (3’ and 5’), 122.5 (6), 118.3 (4), 117.6 
(2), 67.2 (10).  
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Synthesis of furan-2-ylmethyl 4'-(trifluoromethyl)biphenyl-3-ylcarbamate (2c) 
 
CDI (273 mg, 1.68 mmol, 2 eq.), DMAP (51.0 mg, 0.42 mmol, 0.5 eq.) and 4b (200 mg, 0.843 mmol, 
1 eq.) were mixed in dry AcCN (8 ml) and heated at reflux for 24 h; Freshly distilled 2-furfuryl 
alcohol (437 μl, 10.1 mmol, 6 eq.) was added and the reaction heated at 100°C overnight. 
After cooling to r.t, the solvent was removed by evaporation and the crude product purified by 
chromatography on silica gel (petroleum ether:EtOAc, 85:15 followed by 70:30); the obtained yellow 
solid was dissolved in CH2Cl2 and crystallised adding cold n-hexane giving the white crystalline 
product 2c in poor yeld ( 213 mg, 0.59 mmol, 70%). 
 
MM=361.3 g/mol 
 
TLC (Rf=0.63, petroleum ether:ethyl acetate, 80:20).  
 
mp: 119.2-120.0 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.74 (1H, br.s, 2-H), 7.72-7.67 (4H, m, 2’- 3’- 5’ and 6’-H), 
7.48 (1H, dd, J=1.7, <1 Hz, 14-H), 7.42 (1H, t, J=7.8 Hz, 5-H), 7.36 (1H, d, J=8.0 Hz, 6-H), 7.32 (1H, 
dt, J=7.4, 1.4 Hz, 4-H), 6.78 (1H, br.s, 7-NH), 6.51 (1H, d, J=3.2 Hz, 12-H), 6.41 (1H, dd, J=5.9, 2.7 
Hz, 13-H), 5.21 (2H, s, 10-H). 
 
13C NMR: δ (ppm) 153.0 (9), 149.5 (11), 144.3 (3), 143.5 (14), 140.8 (1’), 138.3 (1), 129.4 (5 and 
4’), 127.5 (2’ and 6’), 125.7 (3’ and 5’), 122.5 (4 and 8), 118.4 (6), 117.4 (2), 110.9 (12), 110.7 (13), 
58.8 (10). 
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Synthesis of intermediate 4'-fluoro-[1,1'-biphenyl]-3-amine (4c) 
 
4-Fluorophenylboronic acid (500 mg, 3.57 mmol, 1 eq.), Na2CO3 (758 mg, 7.15 mmol, 2 eq.) and 3-
bromoaniline (584 μl, 5.36 mmol, 1.5 eq.) were mixed in CH3OH (8 ml). Pd(PPh3)4 (140 mg, 0.12 
mmol, 0.034 eq.) was added under argon and the reaction was heated at reflux for 10 h, obtaining a 
dark suspension. 
After cooling to r.t, the mixture was diluted with methanol and filtered through celite to remove the 
black precipitate; water was added and the aqueous phase was washed with 2x15 ml CH2Cl2. 
The organic fractions were combined and dried over anhydrous Na2SO4, filtered and evaporated to 
give a black oil; the crude product was purified by chromatography on silica gel (petroleum 
ether:CH3OH, 90:10 followed by 75:15) and crystallisation with CH2Cl2/cold n-hexane gave rise to 
the final product 4c (436 mg, 2.32 mmol, 65%) which is an ochre powder. 
 
MM=187.2 g/mol 
 
TLC (Rf=0.46, petroleum ether:ethyl acetate, 80:20).  
 
mp: 63.6-64.9 °C 
 
1H NMR (CD3OD, 500 MHz): (ppm) 7.58 (2H, m, 2’- and 6’-H), 7.19-7.12 (3H, m, 5- 3’- and 5’-
H ), 6.96 (1H, t, J=1.9 Hz, 2-H), 6.93-6.8 (1H, m, J=7.0 Hz, 6-H), 6.72 (1H, ddd, J=7.9, 2.2, <1 Hz, 
4-H).  
 
13C NMR: δ (ppm) 163.4 (4’), 147.8 (3), 140.9 (1), 137.9 (1’), 129.2 (5), 128.3 (2’ and 6’), 116.5 
(6), 116.5 (6), 114.9 (3’ and 5’), 114.2 (4), 113.6 (2). 
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Synthesis of cyclohexyl (4'-fluoro-[1,1'-biphenyl]-3-yl)carbamate (3a) 
 
To a solution of 4c (200 mg, 1.07 mmol, 1 eq.) in dry AcCN (8 ml), CDI (693 mg, 4.27 mmol, 4 eq.) 
and DMAP (27.0 mg, 0.214 mmol, 0.2 eq.) were added and the mixture heated at reflux overnight; 
cyclohexanol (1.13 ml, 10.7 mmol, 10 eq.) was added to the obtained red solution and the reaction 
heated at 100°C for 24 h.  
After cooling to r.t, the solvent was removed and the crude product purified by chromatography on 
silica gel (petroleum ether:EtOAc, 90:10 followed by 80:20) giving a colourless oil; that was treated 
with cold n-hexane to give final product 3a as a white powder (247.8 mg, 0.79 mmol, 74%). 
 
MM=313.4 g/mol 
 
TLC (Rf=0.59, petroleum ether:ethyl acetate, 80:20).  
 
mp: 124.6-125.0 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.70 (1H, s, 2-H), 7.57 (2H, dd, J=8.7, 5.3 Hz, 2’- and 6’-H), 
7.38 (1H, t, J=7.8 Hz, 5-H), 7.32 (1H, d, J=8.3 Hz, 4-H), 7.25 (1H, d, J=7.6 Hz, 6-H), 7.13 (2H, t, 
J=8.7 Hz, 3’- and 5’-H), 6.68 (1H, s, 7-NH), 4.83-4.75 (1H, m, 9-CH), 2.01-1.94 (2H, m, 10-Heq and 
14-Heq), 1.80-1.75 (2H, m, 11-Heq and 13-Heq), 1.64-1.55 (1H, m, 12-Heq), 1.53-1.46 (2H, m, 10-Hass 
and 14-Hass), 1.46-1.38 (2H, m, 11-Hass and 13-Hass), 1.33-1.25 (1H, m, 12-Hass). 
 
13C NMR: δ (ppm) 163.6 (4’), 153.2 (8), 141.2 (1), 138.6 (1’), 136.9 (3), 129.5 (2’ and 6’), 128.8 (5), 
121.9 (6), 117.3 (2), 115.7 (3’ and 5’), 115.5 (4), 73.9 (9), 32.0 (10 and 14), 25.4 (12), 23.8 (11 and 
13). 
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Synthesis of benzyl (4'-fluoro-[1,1'-biphenyl]-3-yl)carbamate (3b) 
 
CDI (693 mg, 4.27 mmol, 4 eq.), DMAP (27.0 mg, 0.23 mmol, 0.2 eq.) and 4c (200 mg, 1.07 mmol, 
1 eq.) were mixed in dry AcCN (8 ml) and heated at reflux overnight; phenyl methanol (1100 μl, 
10.68 mmol, 10 eq.) was added and the reaction heated at 100°C for 24 h. 
The reaction was cooled to r.t, the solvent was removed by evaporation and the crude product purified 
by chromatography on silica gel (petroleum ether:EtOAc 85:15) giving a white semisolid; this was 
dissolved in CH2Cl2 and crystallised by adding cold n-hexane leading to product 3b (273.3 mg, 0.85 
mmol, 80%) as a white powder. 
 
MM=321.3 g/mol 
 
TLC (Rf=0.55, petroleum ether:ethyl acetate, 80:20).  
 
mp: 82.2-82.8 °C 
 
1H NMR (CDCl3, 500 MHz): (ppm) 7.64 (1H, d, 2-H), 7.55 (2H, t, J=5.8 Hz, 2’- and 6’-H), 7.47-
7.40 (3H, t, J=9.2 Hz, 11- 13- and 15-H), 7.39 (3H, m, 5- 12- and 14-H), 7.33 (1H, d, J=7.3 Hz, 4-H), 
7.27 (1H, d, J=7.5 Hz, 6-H), 7.14 (2H, t, J=8.5 Hz, 3’- and 5’-H), 6.79 (1H, br.s, 7-NH), 5.25 (2H, s, 
9-CH2). 
 
13C NMR: δ (ppm) 163.6 (4’), 153.6 (8), 141.3 (1), 136.9 (3), 136.5 (1’), 136.0 (10), 129.6 (5), 128.9 
(2’ and 6’), 128.7 (12 and 14), 128.5 (13), 128.4 (11 and 15), 122.3 (6), 117.5 (4), 117.3 (2), 115.5 
(3’ and 5’), 67.2 (9). 
 
